CN113045476A

CN113045476A - Monosubstituted or disubstituted indole derivatives as inhibitors of dengue virus replication

Info

Publication number: CN113045476A
Application number: CN202110222667.6A
Authority: CN
Inventors: B.R.R.科斯特勒恩; J-F.邦范蒂; T.H.M.乔恩克斯; P.J-M.B.拉博伊斯森; D.A.M-E.巴迪奥特; A.D.M.马钱德
Original assignee: Katholieke Universiteit Leuven; Janssen Pharmaceuticals Inc
Current assignee: Katholieke Universiteit Leuven; Janssen Pharmaceuticals Inc
Priority date: 2015-05-08
Filing date: 2016-05-04
Publication date: 2021-06-29
Anticipated expiration: 2036-05-04
Also published as: AU2020273314B2; GT201700234A; JP2022166289A; US10919854B2; US20210171462A1; ES2877404T3; IL272814B; MX383932B; CN111303000B; JP6898493B2; CR20200152A; EP3896072A1; PL3294738T3; AU2016259677B2; PH12017502000A1; CO2017012381A2; JOP20160086B1; KR102610493B1; MD3294738T2; NZ765879A

Abstract

The present invention relates to mono-or di-substituted indole compounds, methods of preventing or treating dengue viral infections by using said compounds, and also to said compounds for use as a medicament, more preferably for use as a medicament for treating or preventing dengue viral infections. Furthermore, the present invention relates to pharmaceutical compositions or combined preparations of these compounds, to compositions or preparations for use as a medicament, more preferably for the prevention or treatment of dengue virus infection. The invention also relates to processes for preparing these compounds.

Description

Monosubstituted or disubstituted indole derivatives as inhibitors of dengue virus replication

Background

Flaviviruses transmitted by mosquitoes or ticks cause life threatening infections such as encephalitis and hemorrhagic fever in humans. Four different but closely related serotypes of dengue fever of flaviviruses are known, the so-called DENV-1, DENV-2, DENV-3 and DENV-4. Dengue is endemic in most tropical and subtropical regions of the world, mainly in urban and semi-urban regions. According to the World Health Organization (WHO), 25 million people (of which 10 million children) are at risk for DENV infection (WHO, 2002). It is estimated that 5000 to 1 million cases of dengue [ DF ], 50 million cases of severe dengue disease (i.e., dengue hemorrhagic fever [ DHF ] and dengue shock syndrome [ DSS ]) and more than 20,000 deaths occur worldwide each year. DHF has become a leading cause of hospitalization and death among children in endemic areas. In summary, dengue fever represents the most common cause of arbovirus (arboviral) disease. The number of dengue cases has risen dramatically over the past few years due to recent outbreaks in countries located in latin america, south east asia and the western pacific (including brazil, puerto rico, venezuela, cambodia, indonesia, vietnam, thailand). Not only does the number of dengue cases increase, but outbreaks tend to be more severe as the disease spreads to new regions.

For the prevention and/or control of diseases associated with dengue virus infection, the only currently available approach is a mosquito eradication strategy to control the vector. Although progress is being made in the development of vaccines against dengue fever, a number of difficulties are encountered. These difficulties include the existence of a phenomenon known as antibody-dependent enhancement (ADE). Recovery from infection with one serotype provides lifelong immunity against that serotype, but confers only partial and transient protection against subsequent infection with one of the other three serotypes. After infection with another serotype, the pre-existing heterologous antibody forms a complex with the newly infected dengue virus serotype, but does not neutralize the pathogen. In contrast, it is believed that viral entry into cells is facilitated, resulting in uncontrolled viral replication and higher peak viral titers. Higher viral titers are associated with more severe dengue disease in both primary and secondary infections. This may be one of the reasons that children are more affected by severe dengue disease than adults, since maternal antibodies can be easily delivered to infants by breast-feeding.

In areas with simultaneous circulation of two or more serotypes (also referred to as superendemic regions), the risk of severe dengue disease is significantly higher due to the increased risk of experiencing secondary, more severe infections. Furthermore, in the case of superepidemics, the probability of the emergence of more virulent strains increases, which in turn increases the probability of Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome.

Dengue-carrying mosquitoes, including Aedes aegypti (Aedes aegypti) and Aedes albopictus (Aedes albopictus) (tiger mosquito), move north on earth. According to the United States (US) centers for disease control and prevention (CDC), two species of mosquitoes are currently ubiquitous in south texas. The north-bound spread of dengue-bearing mosquitoes is not limited to the united states, but has also been observed in europe.

Recently (12 months 2015), dengue vaccines produced by Sanofi Pasteur were first approved in mexico. The vaccine has also been approved in brazil, philippines and salvador. The regulatory review process is continued in other countries where dengue is a public health priority. Nevertheless, the vaccine leaves considerable room for improvement due to the limited efficacy, especially against DENV-1 and DENV-2, low efficacy and lengthy dosing regimen in subjects with a primary infection with flavivirus.

Despite these disadvantages, the vaccine is a regulator of epidemic proportions, as it will provide protection for a large proportion of the population, but may not protect very small infants, who carry the greatest burden of dengue fever. Furthermore, the very limited dosing regimen and efficacy in subjects with flavivirus primary infection makes it inappropriate and potentially cost effective for travelers from non-endemic areas to dengue endemic areas. The above-mentioned disadvantage of dengue vaccines is the reason why pre-exposure to a prophylactic dengue antiviral is required.

Furthermore, specific antiviral drugs for the treatment or prevention of dengue virus infection are not currently available. Clearly, there remains a great unmet medical need for therapeutic agents for the prevention or treatment of viral infections in animals, more particularly in humans, and in particular against viral infections caused by flaviviruses, more particularly dengue viruses. Compounds with good antiviral efficacy, no or low levels of side effects, broad spectrum activity against multiple dengue virus serotypes, low toxicity, and/or good pharmacokinetic or pharmacodynamic properties are highly desirable.

The present invention now provides mono-or di-substituted indole derivatives of compounds that show highly potent activity against all four (4) dengue virus serotypes. Furthermore, the compounds according to the invention have good pharmacokinetic characteristics and surprisingly these specific compounds show improved chiral stability.

Summary of The Invention

The present invention is based on the surprising discovery that at least one of the above-mentioned problems can be solved by the present compounds of the present invention.

The present invention provides compounds that have been shown to have potent antiviral activity against all four (4) serotypes currently known. Furthermore, the present invention demonstrates that these compounds effectively inhibit the proliferation of dengue virus (DENV). These compounds thus constitute a useful class of effective compounds useful for the treatment and/or prevention of viral infections in animals, mammals and humans, more particularly for the treatment and/or prevention of dengue virus infections.

Furthermore, the present invention relates to the use of such compounds as a medicament and to the use thereof for the manufacture of a medicament for the treatment and/or prevention of viral infections, in particular infections by viruses belonging to the dengue virus family, in animals or mammals, more particularly in humans. The invention also relates to processes for the preparation of all such compounds and to pharmaceutical compositions comprising an effective amount of these compounds.

The invention also relates to a method of treating or preventing dengue virus infection in a human by administering to a patient in need thereof an effective amount of one or more of such compounds or a pharmaceutically acceptable salt thereof, optionally in combination with one or more other drugs like another antiviral agent or a dengue vaccine or both.

One aspect of the present invention is to provide compounds of formula (I)

A stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof, which compound comprises a mono-or di-substituted indole group; the compound is selected from the group consisting of:

R₁is H, R₂Is F and R₃Is H or CH₃，

R₁Is H, CH₃Or F, R₂Is OCH₃And R is₃Is a compound of formula (I) wherein the compound is H,

R₁is H, R₂Is OCH₃And R is₃Is CH₃，

R₁Is CH₃，R₂Is F and R₃Is a compound of formula (I) wherein the compound is H,

R₁is CF₃Or OCF₃，R₂Is H and R₃Is a compound of formula (I) wherein the compound is H,

R₁is OCF₃，R₂Is OCH₃And R is₃Is H and

R₁is OCF₃，R₂Is H and R₃Is CH₃。

In particular, the compounds of the present invention or stereoisomeric forms, pharmaceutically acceptable salts, solvates or polymorphs thereof are selected from the group consisting of:

another aspect of the present invention is a compound represented by the following structural formula (I)

R₁is H, R₂Is F and R₃Is H or CH₃，

R₁Is H, CH₃Or F, R₂Is OCH₃And R is₃Is H and

R₁is H, R₂Is OCH₃And R is₃Is CH₃，

R₁is OCF₃，R₂Is OCH₃And R is₃Is H and

R₁is OCF₃，R₂Is H and R₃Is CH₃

Use for inhibiting replication of one or more dengue viruses in a biological sample or patient.

Also part of the invention is a pharmaceutical composition comprising a compound of formula (I) or a stereoisomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts as well as base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-toxic salts.

The compounds of the present invention may also exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules (e.g., ethanol).

The term "polymorph" means that a compound of the invention can exist in more than one form or crystal structure.

The compounds of the present invention may be administered as crystalline or amorphous products. It can be obtained, for example, in the form of a solid filler, powder or film by methods such as precipitation, crystallization, freeze drying, spray drying or evaporation drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. Typically, they will be administered as a formulation in combination with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than one or more compounds of the present invention. The choice of excipient will generally depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

The compounds of the invention or any subgroup thereof may be formulated in different pharmaceutical forms for administration purposes. As suitable compositions, all compositions usually used for systemic administration of drugs can be cited. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. Desirably, these pharmaceutical compositions are in unit dosage forms suitable for, e.g., oral or rectal administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, and the like, in the case of oral liquid preparations (e.g., suspensions, syrups, elixirs, emulsions, and solutions); or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral unit dosage form in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations which can be converted to liquid form shortly before use.

It is particularly advantageous to formulate the above pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets (powder packets), wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

One of ordinary skill in the art of treatment of infectious diseases will be able to determine the effective amount from the test results presented below. Generally, it is contemplated that the daily effective amount will be from 0.01mg/kg to 50mg/kg body weight, more preferably from 0.1mg/kg to 10mg/kg body weight. The desired dose may suitably be administered as two, three, four or more sub-doses at appropriate time intervals throughout the day. The sub-doses may be formulated in unit dosage forms, for example containing from 1 to 1000mg, and in particular from 5mg to 200mg, of active ingredient per unit dosage form.

As is well known to those of ordinary skill in the art, the precise dose and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient, and other drugs that the individual may take. Furthermore, it will be apparent that the effective amount may be reduced or increased according to the response of the subject being treated and/or according to the evaluation of the physician prescribing the compounds of the instant invention. Accordingly, the effective amount ranges described above are merely guidance and are not intended to limit the scope or use of the invention in any way.

The present disclosure is also intended to include any isotopes of atoms present in the compounds of the invention. For example, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include C-13 and C-14. The compounds used in the present invention may also exist in their stereochemically isomeric forms, thereby defining all possible compounds which are not interchangeable, consisting of the same atoms bonded by the same bond sequence, but having different three-dimensional structures. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess.

The mixture may comprise all diastereomers and/or enantiomers of the basic molecular structure of the compound. All stereochemically isomeric forms of the compounds used in the present invention, in pure form or in admixture with each other, are intended to be embraced within the scope of the present invention, including any racemic mixture or racemate.

Pure stereoisomeric forms of the compounds and intermediates mentioned herein are defined as isomers of other enantiomeric or diastereomeric forms which do not have substantially the same basic molecular structure as the compounds or intermediates. In particular, the term 'stereoisomerically pure' relates to a compound or intermediate having a stereoisomeric excess of at least 80% (i.e. a minimum of 90% of one isomer and a maximum of 10% of the other possible isomers) to 100% (i.e. 100% of one isomer and no other isomers), more particularly a compound or intermediate having a stereoisomeric excess of 90% to 100%, even more particularly a stereoisomeric excess of 94% to 100% and most particularly a stereoisomeric excess of 97% to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar manner, but in the discussion concerning the enantiomeric excess and the diastereomeric excess, respectively, in a mixture.

Pure stereoisomeric forms of the compounds and intermediates used in the present invention may be obtained by application of art-known procedures. For example, enantiomers can be separated from each other by selective crystallization of their diastereomeric salts with optically active acids or bases. Examples of these are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. The pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a particular stereoisomer is desired, the compound will be synthesized by stereospecific methods of preparation. These processes will advantageously use enantiomerically pure starting materials.

General synthetic method

The synthesis of compounds having general formula I can be performed as outlined in scheme 1. 2- (4-chloro-2-methoxyphenyl) acetic acid (II) can be converted into the corresponding 2- (4-chloro-2-methoxyphenyl) acetyl chloride (III) with a chlorinating agent, such as, for example, thionyl chloride. Can useLewis acid (Lewis acid) reagents (e.g. like Et)₂AlCl or TiCl₄) In a suitable solvent (such as, for example, CH)₂Cl₂Or 1, 2-dichloroethane) and under suitable reaction conditions typically (but not exclusively) involving cooling, to provide a 3-acylated indole of the general formula V. Introduction of the aniline moiety in the alpha position to the carbonyl moiety of the compound of formula V may be accomplished by a reaction sequence involving, for example, bromination of V with a reagent such as, for example, phenyltrimethylammonium tribromide in a suitable solvent such as, for example, THF to provide the compound of formula VI, and reaction of the compound of formula VI with 3-methoxy-5- (methylsulfonyl) aniline (VII) in a suitable solvent such as, for example, CH₃CN) and typically a base (such as, for example, TEA or DIPEA) is used to provide the compound of formula I as a racemic mixture. Chiral separation of compounds having the general formula I can be performed by, for example, chiral chromatography to provide enantiomers a and B having the general formula I.

Scheme 1

In some cases, synthesis of intermediates having general formula V via the friedel-crafts synthetic pathway benefits from the presence of a Protecting Group (PG) at indole-N during the friedel-crafts reaction step, as outlined in scheme 2. For this purpose, substituted indoles of formula IV can be first converted to N-protected intermediates of formula VIII, such as, for example, N-tosylated intermediates of formula VIII (PG ═ Ts), using a reagent such as, for example, tosyl chloride in the presence of a base such as, for example, sodium hydride. Lewis acid reagents (such as, for example, Et) may be used₂AlCl or TiCl₄) In a suitable solvent (such as, for example, CH)₂Cl₂Or 1, 2-dichloroethane) and under suitable reaction conditions typically (but not exclusively) involving cooling, substituted indoles having the general formula IVFriedel-crafts reaction with acid chloride III to provide a 3-acylated N-protected indole having the formula IX. Removal of the indole-N protecting group PG of the intermediate having formula IX may be accomplished with a reagent such as, for example, LiOH (for PG ═ Ts) in a solvent mixture such as, for example, THF/water at a suitable reaction temperature to provide a 3-acylated indole having formula V.

Scheme 2

As an alternative, intermediates having general formula V may also be prepared as outlined in scheme 3: the N-Boc-protected substituted indole-3-carbaldehyde having the general formula X can be converted into the corresponding Strecker (Strecker) type of intermediate having the general formula XI by reaction with morpholine in the presence of a reagent such as, for example, sodium cyanide and sodium bisulfite, and in a suitable solvent such as, for example, a mixture of water and a water-miscible organic solvent such as, for example, dioxane. Alkylation of a compound of formula XI with 4-chloro-2-methoxy-benzyl chloride can be carried out in the presence of a base such as, for example, potassium hexamethyldisilazane and in a suitable solvent such as, for example, DMF to provide a compound of formula XII. Subjecting the compound having formula XII to suitable aqueous acidic hydrolysis conditions (such as, for example, by treatment with aqueous hydrochloric acid at elevated temperature) provides an intermediate having formula V.

Scheme 3

Examples of the invention

LC/MS method

High Performance Liquid Chromatography (HPLC) measurements were performed using LC pumps, Diode Arrays (DADs) or UV detectors and columns as specified in the corresponding methods. Additional detectors were included if necessary (see method table below).

The flow from the column is brought to a Mass Spectrometer (MS) equipped with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set tuning parameters (e.g. scan range, residence time, etc.) in order to obtain ions of nominal monoisotopic Molecular Weight (MW) that allow identification of compounds. Data acquisition is performed using appropriate software.

By which the retention time (R) is determined_t) And an ion describing compound. The reported molecular ion corresponds to [ M + H ] if not specified differently in the data sheet]⁺(protonated molecules) and/or [ M-H]^-(deprotonated molecules). In the case where the compound is not directly ionizable, the type of adduct (i.e., [ M + NH ]) is specified₄]⁺、[M+HCOO]^-Etc.). For molecules with multiple isotopic patterns (Br, Cl), the reported values are the values obtained for the lowest isotopic mass. All results obtained have experimental uncertainties, which are generally related to the method used.

Hereinafter, "SQD" means a single quadrupole detector, "MSD" mass selective detector, "RT" room temperature, "BEH" bridged ethylsiloxane/silica hybrid, "DAD" diode array detector, "HSS" high intensity silica.

LCMS method code (flow in mL/min; column temperature (T) in deg.C; run time in minutes)

SFC-MS method

Performing an analytical Supercritical Fluid Chromatography (SFC) measurement using an SFC system, the system consisting of: binary pumps for delivering carbon dioxide (CO2) and modifiers, autosampler, column oven, diode array detector equipped with high pressure flow cell withstanding 400 bar. If a Mass Spectrometer (MS) is provided, the flow from the column is brought to that (MS). It is within the knowledge of the skilled person to set tuning parameters (e.g. scan range, residence time, etc.) in order to obtain ions of nominal monoisotopic Molecular Weight (MW) that allow identification of compounds. Data acquisition is performed using appropriate software.

Analytical SFC-MS method (flow in mL/min; column temperature (T) in ℃ C.; run time in minutes and Back Pressure (BPR) in bars).

Melting Point

The values are either peak or melting ranges, and the values obtained have the experimental uncertainties normally associated with such analytical methods.

DSC823e (denoted as DSC)

For many compounds, melting points were determined by DSC823e (Mettler-Toledo). Melting points were measured using a temperature gradient of 10 ℃/min. The maximum temperature was 300 ℃.

Optical rotation:

optical rotation was measured on a platinum Elmer (Perkin-Elmer)341 polarimeter with a sodium lamp and reported as follows: [ alpha ] ° (lambda, cg/100ml, solvent, T ℃).

[α]_λ ^T(100 α)/(l x c): where l is the path length in dm and c is the concentration in g/100ml for the sample at temperature T (. degree. C.) and wavelength λ in nm. If the light wavelength used is 589nm (sodium D line), the symbol D may be used instead. The rotation sign (+ or-) should always be given. When using this equation, the concentration and solvent are often provided in parentheses after the rotation. The degrees of use report rotations and concentrations are given without units (assumed to be g/100 ml).

Example 1:synthesis of 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone (Compound 1) toAnd chiral separation into enantiomers 1A and 1B.

Synthesis of intermediate 1 a:

2- (4-chloro-2-methoxyphenyl) acetic acid [ CAS 170737-95-8] (5.8g, 28.9mmol) was added in small portions to thionyl chloride (50mL) and the resulting solution was stirred at 60 ℃ overnight. The solvent was concentrated under reduced pressure and co-evaporated with toluene to give 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (6.5g) as an oily residue, which was used in the next step without further purification.

Synthesis of intermediate 1 b:

diethylaluminum chloride 1M in hexane (37.1mL, 37.1mmol) was added dropwise to 6-fluoro-1H-indole [ CAS 399-51-9 ] at 0 deg.C](3.34g, 24.76mmol) in CH₂Cl₂(100 mL). After 30min at 0 deg.C, 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (6.3g, 28.76mmol) was slowly added to CH at 0 deg.C₂Cl₂(100 mL). The reaction was stirred at 0 ℃ for 3 h. Ice water was added and the precipitate was filtered off, water and a small amount of CH₂Cl₂And (6) washing. The solid was dried overnight at 70 ℃ under vacuum to give 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) ethanone 1b (4.9 g).

Synthesis of intermediate 1 c:

phenyltrimethylammoniumbromide [ CAS 4207-56-1] at 0 deg.C]A solution of (5.8g, 15.4mmol) in THF (65mL) was added dropwise to a mixture of 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) ethanone 1b (4.9g, 15.4mmol) in THF (60 mL). The mixture was stirred at 0 ℃ for 1h and at room temperature for 2.5 h. The precipitate was filtered off and washed with EtOAc. The combined filtrates were concentrated under reduced pressure. The residue was taken up in EtOAc and washed with water. The precipitate appeared in the organic layer and was filtered off and dried to provide the first crop of 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) ethanone 1c (4.6 g). The organic layer was separated over MgSO₄Dry, filter and evaporate the solvent under reduced pressure. The residue was crystallized from EtOAc and the precipitate was filtered off and washed with Et₂O washed and dried under vacuum to afford a second portion of 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) ethanone 1c (1.6 g).

Synthesis of compound 1 and chiral separation of enantiomers 1A and 1B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) ethanone 1c (3g, 7.56mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](2.28mg, 11.35mmol) and diisopropylethylamine (1.95mL, 11.35mmol) in CH₃A mixture of CN (60mL) and THF (30mL) was stirred at 70 ℃ for 24 h. The reaction was diluted with EtOAc. The organic layer was washed with 1N HCl (twice) and water over MgSO₄Dry, filter and concentrate the solvent under reduced pressure. By flash chromatography on silica gel (15-40 μm, 80g, mobile phase: CH)₂Cl₂MeOH 99.5/0.5) to purify the residue. By flash chromatography on silica gel (15-40 μm, 80g, mobile phase: CH)₂Cl₂MeOH 99.7/0.3) for the second purification. The pure fractions were combined and concentrated under reduced pressure to give 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone as a racemic mixture (compound 1, 2 g).

Via chiral SFC (stationary phase:

AD-H5 μm 20 × 250mm, mobile phase: 50% CO₂50% MeOH) to give 740mg of the first eluting enantiomer and 720mg of the second eluting enantiomer. From CH₃CN/Et₂The first eluting enantiomer was crystallized from O. The precipitate was filtered off and dried to give enantiomer 1A (645 mg). From CH₃CN/Et₂The second eluting enantiomer was crystallized in O. The precipitate was filtered off and dried to give enantiomer 1B (632 mg).

Compound 1:

¹H NMR(500MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)4.00(s，3H)6.24(d，J＝7.9Hz，1H)6.58(s，2H)6.91(s，1H)6.97(dd，J＝8.7，1.9Hz，1H)7.02-7.09(m，2H)7.12(d，J＝1.9Hz，1H)7.27(dd，J＝9.5，1.9Hz，1H)7.35(d，J＝8.5Hz，1H)8.14(dd，J＝8.7，5.5Hz，1H)8.44(s，1H)12.10(br.s.，1H)

LC/MS (method LC-C): r_t3.08min，MH⁺517

Melting point: 174 deg.C

Enantiomer 1A:

¹H NMR(500MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)4.00(s，3H)6.24(d，J＝7.9Hz，1H)6.59(s，2H)6.91(s，1H)6.97(dd，J＝8.8，2.2Hz，1H)7.02-7.10(m，2H)7.12(d，J＝2.2Hz，1H)7.27(dd，J＝9.6，2.2Hz，1H)7.35(d，J＝8.2Hz，1H)8.14(dd，J＝8.8，5.7Hz，1H)8.44(s，1H)12.10(br.s.，1H)

LC/MS (method LC-C): r_t3.09min，MH⁺517

[α]_D ²⁰：+130.3°(c 0.277，DMF)

Chiral SFC (method SFC-D): r_t3.41min，MH⁺517 and chiral purity 100%.

Melting point: 220 deg.C

Enantiomer 1B:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)4.00(s，3H)6.24(d，J＝7.6Hz，1H)6.53-6.65(m，2H)6.91(s，1H)6.97(dd，J＝8.6，2.0Hz，1H)7.01-7.09(m，2H)7.12(d，J＝2.0Hz，1H)7.27(dd，J＝9.6，2.0Hz，1H)7.35(d，J＝8.1Hz，1H)8.14(dd，J＝8.6，5.6Hz，1H)8.43(s，1H)12.09(br.s.，1H)

LC/MS (method LC-C): r_t3.09min，MH⁺517

[α]_D ²⁰：-135.3°(c 0.283，DMF)

Chiral SFC (method SFC-D): r_t4.89min，MH⁺517 and the chiral purity is 99.35 percent.

Melting point: 218 deg.C

Example 1.1: chiral stability of enantiomer 1A at pH 7.4

The chiral stability of enantiomer 1A (R ═ OMe) was evaluated by determining the enantiomeric excess (ee%) after incubation in buffer solution at pH 7.4 at 40 ℃ and 60 ℃ for 24h and 48 h. To assess the effect of the methoxy substituent of enantiomer 1A (R ═ OMe) on stability towards racemization, the chiral stability of enantiomer 1' a (R ═ H) was tested under the same conditions.

For this purpose, 5 μ M buffered (pH 7.4) solutions of 1A and 1 'a were prepared by mixing 25 μ L of a 100 μ M solution of 1A or 1' a in DMSO with 475 μ L of an aqueous buffer (pH 7.4). Samples were taken 24h and 48h after incubation at 40 ℃ and 60 ℃. Analytical samples were analyzed by chiral SFC (MS detection) and chiral purity was expressed as enantiomeric excess (ee% ═ enantiomer a-% enantiomer B). Both enantiomers 1A and 1' a had 100% chiral purity prior to their incubation.

Example 2:synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone (compound 2) into enantiomers 2A and 2B.

Synthesis of intermediate 2 a:

diethylaluminum chloride 1M in hexane (20mL, 20.0mmol) was added dropwise to 6-fluoro-7-methyl-1H-indole [ CAS 57817-10-4 ] at 0 deg.C](1.50g, 10.1mmol) in CH₂Cl₂(45 mL). After 30min at 0 ℃ the reaction mixture was allowed to relaxA solution of 2- (4-chloro-2-methoxyphenyl) acetyl chloride (3.30g, 15.1mmol, synthesis: see example 1) in dichloromethane (30mL) was added slowly. The reaction mixture was stirred at 0 ℃ for 3 h. 1M Rochelle's salt solution (50mL) was added and the reaction mixture was stirred at room temperature for 1 h. The solid was filtered off and partitioned between EtOAc and 1N HCl. The phases were separated. The aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine and MgSO₄Dried, filtered and concentrated under reduced pressure. The residue was triturated with EtOAc and heptane. The precipitate was filtered off to give 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) ethanone 2a (2.00 g).

Synthesis of intermediate 2 b:

a solution of phenyltrimethylammonium tribromide [ CAS 4207-56-1] (2.49g, 6.6mmol) in THF (45mL) is added dropwise to a solution of 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) ethanone 2a (2.00g, 6.0mmol) in THF (65mL) at 0 ℃. The mixture was stirred at room temperature overnight. The precipitate was filtered off and washed with EtOAc. The combined filtrates were concentrated under reduced pressure. The residue was taken up with minimal acetonitrile. The precipitate was filtered off, washed with acetonitrile and dried under vacuum to give the first crop of 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) ethanone 2b (1.51 g). The filtrate was concentrated under reduced pressure. The residue was taken up with minimal acetonitrile. The precipitate was filtered off, washed with acetonitrile and dried under vacuum to give a second portion of 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) ethanone 2b (0.70 g).

Synthesis of compound 2 and chiral separation of enantiomers 2A and 2B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) ethanone 2b (1.8g, 4.36mmol) and 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](2.6g, 13.0mmol) in THF (9mL) and CH₃The mixture in CN (9mL) was heated under microwave irradiation at 100 ℃ for 50 min. The reaction mixture was diluted with EtOAc and washed with 1N HCl. The phases were separated. The organic phase was washed with saturated NaHCO₃The aqueous solution and brine were washed over MgSO₄Drying, filtering and reducing pressureAnd (5) concentrating. The residue was taken up with minimal acetonitrile. The precipitate was filtered off, washed with acetonitrile and dried under vacuum to give 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-7-methyl-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone as a racemic mixture (compound 2, 1.7 g).

Through preparative SFC (stationary phase: (S, S) -Whelk-O15 μm 250X21.1mm, mobile phase: 50% CO₂50% MeOH) was performed for chiral separation of the enantiomer of Compound 2(1.59 mg). The product fractions were combined and evaporated under reduced pressure. By column chromatography on silica gel (15-40 μm, 24g, mobile phase: CH)₂Cl₂MeOH 99.5/0.5) to further purify the first eluting enantiomer (746 mg). Pure fractions were combined and evaporated under reduced pressure (560 mg). By using Et₂O and several drops of CH₃A mixture of CN was milled to solidify the residue. The solid was filtered off and dried under vacuum to give enantiomer 2A (473 mg). By column chromatography on silica gel (15-40 μm, 24g, mobile phase: CH)₂Cl₂MeOH 99.5/0.5) to further purify the second eluted enantiomer (732 mg). Pure fractions were combined and evaporated under reduced pressure (550 mg). By using Et₂O and several drops of CH₃A mixture of CN was milled to solidify the residue. The solid was filtered off and dried under vacuum to give enantiomer 2B (457 mg).

Compound 2:

¹H NMR(300MHz，DMSO-d₆)δppm 2.38(d，J＝1.5Hz，3H)3.10(s，3H)3.73(s，3H)4.01(s，3H)6.27(d，J＝7.9Hz，1H)6.55-6.63(m，2H)6.93(m，1H)6.94-7.09(m，3H)7.13(d，J＝1.9Hz，1H)7.35(d，J＝8.3Hz，1H)7.97(dd，J＝8.7，5.3Hz，1H)8.45(s，1H)12.23(br.s，1H)

LC/MS (method LC-D): r_t1.68min，MH⁺531

Enantiomer 2A:

¹H NMR(500MHz，DMSO-d₆)δppm 2.37-2.39(m，3H)3.09(s，3H)3.72(s，3H)4.01(s，3H)6.26(d，J＝7.9Hz，1H)6.54-6.63(m，2H)6.92(s，1H)6.97(dd，J＝8.4，1.9Hz，1H)7.02(dd，J＝9.9，9.0Hz，1H)7.07(d，J＝7.9Hz，1H)7.13(d，J＝1.9Hz，1H)7.35(d，J＝8.4Hz，1H)7.96(dd，J＝8.5，5.4Hz，1H)8.45(s，1H)12.24(br.s.，1H)

LC/MS (method LC-C): r_t3.20min，MH⁺531

[α]_D ²⁰：+104.5°(c 0.2545，DMF)

Chiral SFC (method SFC-A): r_t4.22min，MH⁺531, chiral purity 100%.

Enantiomer 2B:

¹H NMR(500MHz，DMSO-d₆)δppm 2.36-2.41(m，3H)3.09(s，3H)3.72(s，3H)4.01(s，3H)6.26(d，J＝7.9Hz，1H)6.57-6.64(m，2H)6.92(s，1H)6.97(dd，J＝8.2，1.9Hz，1H)6.99-7.04(m，1H)7.07(d，J＝7.9Hz，1H)7.13(d，J＝1.9Hz，1H)7.35(d，J＝8.2Hz，1H)7.96(dd，J＝8.7，5.2Hz，1H)8.45(s，1H)12.24(br.s.，1H)

LC/MS (method LC-C): r_t3.20min，MH⁺531

[α]_D ²⁰：-104.1°(c 0.2536，DMF)

Chiral SFC (method SFC-A): r_t5.12min，MH⁺531, chiral purity 99.53%.

Example 3:synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone (compound 3) into enantiomers 3A and 3B.

Synthesis of intermediate 3 a:

adding NaHSO₃(5.7g, 54.5mmol) in water (45mL) was added to tert-butyl 3-formyl-6-methoxy-1H-indole-1-carboxylate [ CAS 847448-73-1 [ ]](10g, 36.3mmol) in dioxane (45 mL). After 15min, morpholine (4.8mL, 54.5mmol) was added and after 35min, sodium cyanide (NaCN) (1.96g, 40mmol) was added.The resulting suspension was stirred at room temperature for 3 days until the reaction was complete. The product was filtered off and washed with 1/1 mixture of dioxane/water (3x35mL) and then with water (3x45mL) and dried under vacuum at 60 ℃. The solid is dissolved in Et₂O (125mL), filtered off and Et₂O (3x) was washed and dried under vacuum at 50 ℃ to afford tert-butyl 3- (cyano (morpholino) methyl) -6-methoxy-1H-indole-1-carboxylate 3a (12.3 g).

Synthesis of intermediate 3 b:

a mixture of tert-butyl 3- (cyano (morpholino) methyl) -6-methoxy-1H-indole-1-carboxylate 3a (6.0g, 16.2mmol) in dry DMF (80mL) was taken in N₂Stirring under atmosphere while cooling on an ice bath. A 0.5M solution of KHMDS in toluene (35.5mL, 17.8mmol) was added dropwise over 10 min. After stirring for another 10min, 4-chloro-1- (chloromethyl) -2-methoxybenzene [ CAS 101079-84-9 ] was added](3.09g, 16.2mmol) and the resulting mixture was stirred at room temperature for 20 h. The reaction mixture was poured into cold water (400mL) and the product was treated with Et₂O (2x) extraction. The combined organic layers were washed with brine, over MgSO₄Dried, evaporated under reduced pressure and co-evaporated with xylene. The residue was subjected to flash chromatography (stationary phase: Grace)

Silica 120g, mobile phase: heptane/EtOAc gradient 100/0 to 20/80). The desired fractions were combined, evaporated under reduced pressure and co-evaporated with dioxane to give tert-butyl 3- (2- (4-chloro-2-methoxyphenyl) -1-cyano-1-morpholinoethyl) -6-methoxy-1H-indole-1-carboxylate 3b (7.75 g).

Synthesis of intermediate 3 c:

to a stirred suspension of tert-butyl 3- (2- (4-chloro-2-methoxyphenyl) -1-cyano-1-morpholinoethyl) -6-methoxy-1H-indole-1-carboxylate 3b (7.75g, 14.7mmol) in dioxane (40mL) and water (20mL) was added a solution of HCl 6M in isopropanol (36.8mL, 220 mmol). The resulting mixture was stirred at 60 ℃ for 4h and subsequently at 80 ℃ for 1 h. After cooling to room temperature, the mixture was left to stand for 20h to allow crystallization of the reaction product. The product was filtered off and used iPrOH/H₂A 1/1/1 mixture of O/dioxane (2x15mL) was washed and dried under vacuum at 50 ℃ to give 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-1H-indol-3-yl) ethanone 3c (3.67 g).

Synthesis of compound 3 and chiral separation of enantiomers 3A and 3B:

a stirred mixture of 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-1H-indol-3-yl) ethanone 3c (2g, 6.07mmol) in THF (80mL) was stirred in N₂Cooling under atmosphere on an ice bath. Phenyl trimethyl ammonium tribromide [ CAS 4207-56-1] was added](2.39g, 6.37mmol) and the reaction mixture was stirred at 0 ℃ for 1h, and subsequently at room temperature for 1.5 h. Adding 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 ]](3.66g, 18.2mmol) and the solvent was evaporated under reduced pressure. Dissolving the residue in CH₃CN (100 mL). Diisopropylethylamine (2.09mL, 12.1mmol) was added and the reaction mixture was heated at 55 ℃ for 27 h. The reaction mixture was allowed to cool to room temperature and poured slowly into stirred water (400 mL). The product was extracted with 2-MeTHF (2X). The combined organic layers were washed with brine, over MgSO₄Dried, filtered and evaporated under reduced pressure. The residue (8g) was purified by flash chromatography (stationary phase: Grace)

Silica 120g, mobile phase: heptane/EtOAc gradient from 100/0 to 0/100). The desired fractions were combined and evaporated under reduced pressure. The residue (5.4g) was purified by preparative HPLC (stationary phase:

preparation C18OBD-10 μm, 50X150 mm; mobile phase: 0.25% NH in Water₄HCO₃Solution of CH₃CN) for further purification. The product fractions were combined and evaporated under reduced pressure and subsequently co-evaporated with MeOH. From EtOAc (15mL), CH₃CN (2mL) and MeOH (2mL) crystallized the residue. The solid was filtered off, washed with EtOAc (3 ×), and dried under vacuum at 50 ℃ to provide 2- (4-chloro-2-methyl) as a racemic mixtureOxyphenyl) -1- (6-methoxy-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone (compound 3, 681 mg).

Chiral separation of the enantiomer of compound 3(0.63g) was carried out via normal phase chiral separation (stationary phase: AS 20 μm, mobile phase: 100% methanol). The product fractions were combined and evaporated under reduced pressure. By flash chromatography (stationary phase: Grace)

Silica 12g, mobile phase: heptane/EtOAc/EtOH gradient from 100/0/0 to 40/45/15) to purify the first eluting enantiomer. The desired fractions were combined and evaporated and co-evaporated with EtOAc. By reaction at H₂O (4mL) was stirred and MeOH (1.6mL) was added slowly to solidify the remaining oil. After stirring for 20 minutes, the product is filtered off and washed with MeOH/H₂The 1/2 mixture of O was washed (3x) and dried under vacuum at 50 ℃ to afford enantiomer 3A (168mg) as an amorphous solid. By flash chromatography (stationary phase: Grace)

Silica 12g, mobile phase: heptane/EtOAc/EtOH gradient from 100/0/0 to 40/45/15) to purify the second eluting enantiomer. The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with EtOAc. By reaction at H₂O (4mL) was stirred and MeOH (2mL) was added slowly to solidify the remaining foam. After stirring for 15 minutes, the product is filtered off and washed with MeOH/H₂The 1/2 mixture of O was washed (3x) and dried under vacuum at 50 ℃ to afford enantiomer 3B (146mg) as an amorphous solid.

Compound 3:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.77(s，3H)4.01(s，3H)6.21(d，J＝7.9Hz，1H)6.54-6.64(m，2H)6.83(dd，J＝8.7，2.3Hz，1H)6.91(t，J＝1.4Hz，1H)6.94-6.99(m，2H)7.04(d，J＝7.7Hz，1H)7.12(d，J＝2.0Hz，1H)7.35(d，J＝8.1Hz，1H)8.02(d，J＝8.8Hz，1H)8.30(s，1H)11.84(s，1H)

LC/MS (method LC-A): r_t1.20min，MH⁺529

Enantiomer 3A:

¹H NMR(360MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.77(s，3H)4.01(s，3H)6.22(d，J＝8.1Hz，1H)6.55-6.61(m，2H)6.84(dd，J＝8.8，2.2Hz，1H)6.91(t，J＝1.8Hz，1H)6.94-7.00(m，2H)7.07(d，J＝7.0Hz，1H)7.13(d，J＝1.8Hz，1H)7.35(d，J＝8.4Hz，1H)8.02(d，J＝8.8Hz，1H)8.32(d，J＝2.9Hz，1H)11.87(d，J＝2.6Hz，1H)

LC/MS (method LC-A): r_t1.08min，MH⁺529

[α]_D ²⁰：+134.9°(c0.545，DMF)

Chiral SFC (method SFC-E): r_t4.31min，MH⁺529, chiral purity 100%.

Enantiomer 3B:

¹H NMR(360MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.77(s，3H)4.01(s，3H)6.21(d，J＝8.1Hz，1H)6.54-6.62(m，2H)6.83(dd，J＝8.6，2.4Hz，1H)6.91(t，J＝1.5Hz，1H)6.94-6.99(m，2H)7.07(d，J＝7.0Hz，1H)7.13(d，J＝1.8Hz，1H)7.35(d，J＝8.1Hz，1H)8.02(d，J＝8.8Hz，1H)8.32(d，J＝2.9Hz，1H)11.87(br d，J＝2.2Hz，1H)

LC/MS (method LC-A): r_t1.08min，MH⁺529

[α]_D ²⁰：-116.7°(c 0.51，DMF)

Chiral SFC (method SFC-E): r_t4.63min，MH⁺529, chiral purity 94.7%.

Example 4: synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (6-methoxy-5-methyl-1H-indol-3-yl) ethanone (compound 4) into enantiomers 4A and 4B.

Synthesis of intermediate 4 a:

diethylaluminum chloride 1M in hexane (13.5mL, 13.5mmol) was added dropwise to 6-methoxy-5-methyl-1H-indole [ CAS 1071973-95-9 ] at 0 deg.C](1.45g, 9mmol) in CH₂Cl₂(45 mL). After 30min at 0 deg.C, 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (2.4g, 10.9mmol) was slowly added to CH at 0 deg.C₂Cl₂(45 mL). The reaction was stirred at 0 ℃ for 3 h. Ice water was added and the precipitate was filtered off and washed with water. The solid was dried under vacuum to give 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5-methyl-1H-indol-3-yl) ethanone 4a (2.1 g).

Synthesis of intermediate 4 b:

a solution of phenyltrimethylammonium tribromide [ CAS 4207-56-1] (2.4g, 6.4mmol) in THF (65mL) is added dropwise to a mixture of 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5-methyl-1H-indol-3-yl) ethanone 4a (2.1g, 6.1mmol) in THF (60mL) at 0 ℃. The mixture was stirred at 0 ℃ for 1h and at room temperature for 2.5 h. The precipitate was filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was taken up with minimal diisopropyl ether. The precipitate was filtered off and dried under vacuum to give 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5-methyl-1H-indol-3-yl) ethanone 4b (2.36 g).

Synthesis of compound 4 and chiral separation of enantiomers 4A and 4B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5-methyl-1H-indol-3-yl) ethanone 4b (4.0g, 9.46mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4%](2.86g, 14.2mmol) and diisopropylethylamine (2.44mL, 14.2mmol) in CH₃The mixture in CN/THF (1/1) (100mL) was stirred at 45 ℃ for 72 h. The solvent was removed under reduced pressure. The residue was dissolved in EtOAc. The organic layer was washed twice with 1N HCl, twice with water, over MgSO₄Dried, filtered and concentrated under reduced pressure. Reacting the compound with CH₃Crystallization in CN/diisopropyl ether to give 2- (4-chloro-2-methoxyphenyl) as racemic mixture) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (6-methoxy-5-methyl-1H-indol-3-yl) ethanone (compound 4, 1.1 g).

The chiral SFC (stationary phase (S, S) -Whelk-O15 μm 250X21.1mm, mobile phase 45% CO)₂55% MeOH) to give 500mg of the first eluting enantiomer and 531mg of the second eluting enantiomer. Separating the first eluting enantiomer from CH₃CN/Et₂Crystallization in O gave enantiomer 4A (401 mg). Separating the second eluting enantiomer from CH₃CN/Et₂Crystallization in O gave enantiomer 4B (396 mg).

Compound 4:

¹H NMR(500MHz，DMSO-d₆)δppm 2.21(s，3H)3.09(s，3H)3.72(s，3H)3.79(s，3H)4.01(s，3H)6.20(d，J＝7.9Hz，1H)6.58(s，2H)6.88-6.93(m，2H)6.96(dd，J＝8.5，1.9Hz，1H)7.02(d，J＝7.9Hz，1H)7.12(d，J＝1.9Hz，1H)7.34(d，J＝8.5Hz，1H)7.89(s，1H)8.24(s，1H)11.78(br.s.，1H)

LC/MS (method LC-C): r_t3.16min，MH⁺543

Melting point: 208 deg.C

Enantiomer 4A:

¹H NMR(500MHz，DMSO-d₆)δppm 2.21(s，3H)3.09(s，3H)3.72(s，3H)3.79(s，3H)4.01(s，3H)6.20(d，J＝7.6Hz，1H)6.58(d，J＝1.6Hz，2H)6.87-6.93(m，2H)6.96(dd，J＝8.2，1.9Hz，1H)7.02(d，J＝7.6Hz，1H)7.12(d，J＝1.9Hz，1H)7.34(d，J＝8.2Hz，1H)7.89(s，1H)8.25(s，1H)11.78(br.s.，1H)

LC/MS (method LC-C): r_t3.15min，MH⁺543

[α]_D ²⁰：+141.8°(c 0.3936，DMF)

Chiral SFC (method SFC-C): r_t4.95min，MH⁺543, chiral purity 100%.

Melting point: 173 ℃ C

Enantiomer 4B:

¹H NMR(500MHz，DMSO-d₆)δppm 2.21(s，3H)3.09(s，3H)3.72(s，3H)3.79(s，3H)4.01(s，3H)6.20(d，J＝7.9Hz，1H)6.58(s，2H)6.88-6.93(m，2H)6.96(dd，J＝8.2，1.9Hz，1H)7.02(d，J＝7.9Hz，1H)7.12(d，J＝1.9Hz，1H)7.34(d，J＝8.2Hz，1H)7.90(s，1H)8.25(s，1H)11.79(br.s.，1H)

LC/MS (method LC-C): r_t3.15min，MH⁺543

[α]_D ²⁰：-142.2°(c 0.3909，DMF)

Chiral SFC (method SFC-C): r_t6.84min，MH⁺543, chiral purity 100%.

Melting point: 174 deg.C

Example 5:synthesis of 2- (4-chloro-2-methoxyphenyl) -1- (5-fluoro-6-methoxy-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone (compound 5) and chiral separation into enantiomers 5A and 5B.

Synthesis of intermediate 5 a:

diethylaluminum chloride 1M in hexane (15.7mL, 15.7mmol) was added dropwise to 5-fluoro-6-methoxy-1H-indole [ CAS 1211595-72-0 ] at 0 deg.C](2g, 12.1mmol) in CH₂Cl₂(50 mL). After 30min at 0 deg.C, 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (3.2g, 14.6mmol) was slowly added to CH at 0 deg.C₂Cl₂(50 mL). The reaction was stirred at 0 ℃ for 3 h. Ice water was added and the precipitate was filtered off, water and minimal CH₂Cl₂And (6) washing. The solid was dried under vacuum to give 2- (4-chloro-2-methoxyphenyl) -1- (5-fluoro-6-methoxy-1H-indol-3-yl) ethanone 5a (2.82 g).

Synthesis of intermediate 5 b:

phenyltrimethylammoniumbromide [ CAS 4207-56-1] at 0 deg.C]A solution of (3.5g, 8.1mmol) in THF (20mL) was added dropwise to 2- (4-chloro-2-methoxybenzene1- (5-fluoro-6-methoxy-1H-indol-3-yl) ethanone 5a (2.82g, 8.1mmol) in THF (46 mL). The mixture was stirred at 0 ℃ for 1h and at room temperature for 4 h. The precipitate was filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc and washed with water. The organic phase is passed over MgSO₄Dry, filter and evaporate the solvent under reduced pressure. The residue was taken up with minimal EtOAc. The precipitate was filtered off and dried under vacuum to give 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (5-fluoro-6-methoxy-1H-indol-3-yl) ethanone 5b (2.5 g).

Synthesis of compound 5 and chiral separation of enantiomers 5A and 5B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (5-fluoro-6-methoxy-1H-indol-3-yl) ethanone 5b (2.5g, 5.86mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](1.415g, 7.03mmol) and diisopropylethylamine (1.515mL, 8.79mmol) in CH₃A mixture of CN (55mL) and THF (100mL) was stirred at 50 ℃ for 10 days. The solvent was removed under reduced pressure. By flash chromatography on silica gel (15-40 μm, 80g, mobile phase: CH)₂Cl₂/CH₃OH 99.25/0.75) to purify the residue. The pure stages were combined and evaporated. The compound was dissolved in EtOAc and stirred with HCl 1N for 15 min. A precipitate appeared and was filtered off and dried under vacuum to give 2- (4-chloro-2-methoxyphenyl) -1- (5-fluoro-6-methoxy-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone as a racemic mixture (compound 5, 1.3 g).

Via preparative chiral SFC (stationary phase:

IC 5 μm 250x20mm, mobile phase: 55% CO₂45% MeOH) was used for chiral separation of the enantiomer of compound 5. The product fractions were combined and evaporated. The first eluting enantiomer was solidified by trituration with heptane/diisopropyl ether. The solid was filtered off and dried under vacuum to afford enantiomer 5A (502mg) as an amorphous white powder. Curing the second by trituration with heptane/diisopropyl etherThe enantiomers were eluted. The solid was filtered off and dried under vacuum to afford enantiomer 5B as an amorphous white powder (490 mg).

Compound 5:

¹H NMR(500MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.85(s，3H)4.00(s，3H)6.21(d，J＝7.9Hz，1H)6.58(d，J＝1.3Hz，2H)6.90(s，1H)6.97(dd，J＝8.2，1.9Hz，1H)7.06(d，J＝7.9Hz，1H)7.10-7.18(m，2H)7.34(d，J＝8.2Hz，1H)7.82(d，J＝12.0Hz，1H)8.35(s，1H)11.98(br.s.，1H)

LC/MS (method LC-C): r_t3.01min，MH⁺547

Melting point: 182 deg.C

Enantiomer 5A:

¹H NMR(500MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.85(s，3H)4.00(s，3H)6.21(d，J＝7.9Hz，1H)6.58(d，J＝1.3Hz，2H)6.90(s，1H)6.97(dd，J＝8.2，2.0Hz，1H)7.07(d，J＝7.9Hz，1H)7.11-7.17(m，2H)7.34(d，J＝8.2Hz，1H)7.82(d，J＝11.7Hz，1H)8.35(s，1H)11.98(br.s.，1H)

LC/MS (method LC-C): r_t3.00min，MH⁺547

[α]_D ²⁰：+136.4°(c 0.28，DMF)

Chiral SFC (method SFC-B): r_t3.43min，MH⁺547, chiral purity 100%.

Enantiomer 5B:

¹H NMR(500MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.85(s，3H)4.00(s，3H)6.21(d，J＝7.9Hz，1H)6.58(d，J＝1.3Hz，2H)6.90(s，1H)6.97(dd，J＝8.2，2.0Hz，1H)7.07(d，J＝7.9Hz，1H)7.11-7.19(m，2H)7.34(d，J＝8.2Hz，1H)7.82(d，J＝11.7Hz，1H)8.35(s，1H)11.95(br.s.，1H)

LC/MS (method LC-C): r_t3.00min，MH⁺547

[α]_D ²⁰：-126.3°(c 0.2755，DMF)

Chiral SFC (method S)FC-B)：R_t4.80min，MH⁺547, chiral purity 98.06%.

Example 6:synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (6-methoxy-7-methyl-1H-indol-3-yl) ethanone (compound 6) into enantiomers 6A and 6B.

Synthesis of intermediate 6 a:

diethylaluminum chloride 1M in hexane (32.8mL, 32.8mmol) was added dropwise to 6-methoxy-7-methyl-1H-indole [ CAS 19500-05-1 ]](3.53g, 21.9mmol) in CH₂Cl₂(150mL) in a cooled (-30 ℃ C.) solution. After stirring at 30 ℃ for 15min, 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (6.71g, 30.6mmol) was slowly added to CH at-30 ℃₂Cl₂(150 mL). The reaction was stirred at-30 ℃ for 1h and allowed to warm to room temperature while stirring for 2 h. The reaction mixture was poured into ice water/rochelle salt. Passing the mixture through

The pad was filtered and the filter cake was rinsed several times with THF. The layers were separated. The aqueous layer was extracted with THF. The combined organic layers were washed with brine, water, and MgSO₄Dried, filtered and evaporated under reduced pressure. Suspending the solid residue in CH₂Cl₂(50mL) and the solid was filtered off and diluted with a small amount of CH₂Cl₂Washed and dried under vacuum at 50 ℃ to give 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-7-methyl-1H-indol-3-yl) ethanone 6a (6.85g) as an off-white solid.

Synthesis of intermediate 6 b:

phenyltrimethylammoniumbromide [ CAS 4207-56-1] at 0 deg.C]A solution of (8.2g, 21.8mmol) in THF (150mL) was added dropwise to 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-7-methyl-1H-indol-3-yl) ethanone 6a (6.8g, 1)9.8mmol) in THF (250 mL). The mixture was stirred at room temperature for 2 h. The precipitate was filtered off and washed with THF. The filtrate was concentrated under reduced pressure. Separating the residue from CH₂Cl₂And (4) medium crystallization. The precipitate is filtered off and taken up with CH₂Cl₂(2x) washed and dried under vacuum at 50 ℃ to give 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-7-methyl-1H-indol-3-yl) ethanone 6b (5.38 g).

Synthesis of compound 6 and chiral separation of enantiomers 6A and 6B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-7-methyl-1H-indol-3-yl) ethanone 6b (1.96g, 4.65mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 mmol ]](1.40g, 6.97mmol) and diisopropylethylamine (1.20mL, 6.97mmol) in CH₃The mixture in CN (50mL) was heated at reflux overnight. The solvent was removed under reduced pressure. Dissolving the residue in CH₂Cl₂And washed with 0.5N HCl and water, MgSO₄Dried, filtered and evaporated under reduced pressure. By flash chromatography on silica gel (stationary phase:

SNAP Ultra 100g, mobile phase: EtOAc: EtOH (3: 1)/heptane gradient 0/100 to 50/50) to purify the residue. The pure fractions were combined and evaporated under reduced pressure to give 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (6-methoxy-7-methyl-1H-indol-3-yl) ethanone as a racemic mixture (compound 6, 1.0 g).

Via preparative chiral SFC (stationary phase:

diacel OD 20x250mm, mobile phase: CO2₂Containing 0.2% iPrNH₂EtOH) was performed for chiral separation of the enantiomer of compound 6(1.0 g). The product fractions were combined and evaporated. The first eluting enantiomer was solidified by trituration with a MeOH/water (1/1) mixture. The solid was filtered off and dried under vacuum at 50 ℃ to provide the enantiomer as an amorphous white powder6A (368 mg). The second eluting enantiomer was solidified by trituration with a MeOH/water (1/1) mixture. The solid was filtered off and dried under vacuum at 50 ℃ to afford enantiomer 6B (303mg) as an amorphous white powder.

Enantiomer 6A:

¹H NMR(360MHz，DMSO-d₆)δppm 2.29(s，3H)3.10(s，3H)3.72(s，3H)3.80(s，3H)4.02(s，3H)6.24(d，J＝7.7Hz，1H)6.56-6.59(m，1H)6.59-6.62(m，1H)6.92(t，J＝1.6Hz，1H)6.93-6.99(m，2H)7.06(d，J＝7.7Hz，1H)7.13(d，J＝1.8Hz，1H)7.35(d，J＝8.4Hz，1H)7.94(d，J＝8.4Hz，1H)8.35(s，1H)11.91(br s，1H)

LC/MS (method LC-A): r_t1.18min，MH⁺543

[α]_D ²⁰：+122.9°(c 0.48，DMF)

Chiral SFC (method SFC-E): r_t4.15min MH⁺543, chiral purity 100%.

Enantiomer 6B:

¹H NMR(360MHz，DMSO-d₆)δppm 2.29(s，3H)3.10(s，3H)3.72(s，3H)3.80(s，3H)4.02(s，3H)6.24(d，J＝7.7Hz，1H)6.57-6.59(m，1H)6.59-6.62(m，1H)6.92(t，J＝1.8Hz，1H)6.93-7.00(m，2H)7.06(d，J＝＝7.7Hz，1H)7.13(d，J＝1.8Hz，1H)7.35(d，J＝8.1Hz，1H)7.94(d，J＝8.8Hz，1H)8.35(d，J＝2.2Hz，1H)11.91(br s，1H)

LC/MS (method LC-A): r_t1.22min，MH⁺543

[α]_D ²⁰：-120.6°(c 0.2755，DMF)

Chiral SFC (method SFC-E): r_t4.50min，MH⁺543, chiral purity 99.35%.

Example 7: synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-5-methyl-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone (compound 7) into enantiomers 7A and 7B.

Synthesis of intermediate 7 a:

mixing 6-fluoro-5-methyl-1H-indole [ CAS 162100-95-0 ]](1.7g, 11.4mmol) in CH₂Cl₂(100mL) of solution in N₂Cooling to 0 ℃ under atmosphere. A solution of diethylaluminum chloride 1M in hexane (17.1mL, 17.1mmol) was added dropwise and the resulting mixture was kept at 0 ℃ for 15 min. 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (3.50g, 16mmol) was added dropwise to CH₂Cl₂(50 mL). Stirring was continued at 0 ℃ for 1h and at room temperature for 2 h. The reaction mixture was poured into a stirred ice/rochelle salt solution. After the ice has melted, the mixture is passed through

Filter and wash the filter cake several times with THF. The filtrates were combined. The layers were separated and the organic layer was washed with brine, over MgSO₄Dried, filtered and evaporated under reduced pressure. Suspending the solid residue in CH₂Cl₂In (30mL), the precipitate was filtered off and dried under vacuum at 50 ℃ to afford 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-5-methyl-1H-indol-3-yl) ethanone 7a (2.76 g).

Synthesis of intermediate 7 b:

a stirred solution of 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-5-methyl-1H-indol-3-yl) ethanone 7a (2.76g, 8.32mmol) in THF (350mL) was cooled to 0 ℃. A solution of phenyltrimethylammonium tribromide [ CAS 4207-56-1] (3.44g, 9.15mmol) in THF (50mL) was added dropwise. The reaction mixture was stirred at 0 ℃ for 2h and at room temperature for 2 h. The solid was removed by filtration and washed with THF. The combined filtrates were evaporated under reduced pressure. The residue was combined with EtOAc (50 mL). The solid was isolated by filtration, washed with a small amount of EtOAc and dried under vacuum at 50 ℃ to afford 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-5-methyl-1H-indol-3-yl) ethanone 7b (3.21g) as a white solid, which was used in the next step without further purification.

Synthesis of compound 7 and chiral separation of enantiomers 7A and 7B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-5-methyl-1H-indol-3-yl) ethanone 7b (1.6g, 3.90mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](1.18g, 5.84mmol) and diisopropylethylamine (671. mu.L, 3.90mmol) in CH₃The mixture in CN (100mL) was stirred at 85 ℃ overnight. The reaction mixture was concentrated under reduced pressure. Dissolving the residue in CH₂Cl₂(100mL), washed with IN HCl (100mL) and water (100mL), over MgSO₄Dried, filtered and evaporated under reduced pressure. The residue is purified by column chromatography (stationary phase: Grace)

Silica 120g, mobile phase: EtOAc: EtOH (3: 1)/heptane gradient 0/100 to 50/50). The desired fractions were combined and evaporated under reduced pressure. Separating the residue from CH₂Cl₂Precipitation in heptane. The solid was isolated by filtration and washed with CH₂Cl₂Heptane (1/1) wash. By preparative HPLC (stationary phase:

c18 ODB-10 μm, 200g, 5cm, mobile phase: 0.25% NH in Water₄HCO₃Solution of CH₃CN) further purified the crude product. The product fractions were combined and evaporated under reduced pressure. The solid residue was combined with EtOAc (20mL) and the solid was isolated by filtration and washed with a small amount of EtOAc to provide 2- (4-chloro-2-methoxyphenyl) -1- (6-fluoro-5-methyl-1H-indol-3-yl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) ethanone as a racemic mixture (compound 7, 341 mg). The filtrate was evaporated under reduced pressure and the residue was taken up in MeOH. After stirring for 30min, the solid was isolated by filtration to provide a second crop of compound 7(92 mg).

Chiral separation of the enantiomer of compound 7(402mg) was performed via normal phase chiral separation (stationary phase: (S, S) -Whelk-O1, mobile phase: 100% methanol). Product fractions were combined and evaporated to provide asEnantiomer 7A of the first eluted product and enantiomer 7B as the second eluted product. Enantiomer 7A was purified by flash chromatography on silica gel (stationary phase: Grace)

Silica 12g, mobile phase: heptane/EtOAc/EtOH 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure. The residue is washed with H₂O (1.75mL) and MeOH (0.75mL) were triturated. The solid is filtered off and washed with H₂O/MeOH 7/3 was washed (2 ×) and dried under vacuum at 50 ℃ to provide enantiomer 7A (48 mg). Enantiomer 7B was purified by flash chromatography on silica gel (stationary phase: Grace)

Silica 12g, mobile phase: heptane/EtOAc/EtOH 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure. The residue is washed with H₂O (1.75mL) and MeOH (0.75mL) were triturated. The solid is filtered off and washed with H₂O/MeOH 7/3 was washed (2 ×) and dried under vacuum at 50 ℃ to provide enantiomer 7B (43 mg).

Compound 7:

¹H NMR(400MHz，DMSO-d₆)δppm 2.30(d，J＝0.9Hz，3H)3.09(s，3H)3.72(s，3H)4.00(s，3H)6.22(d，J＝7.7Hz，1H)6.54-6.63(m，2H)6.92(t，J＝1.5Hz，1H)6.97(dd，J＝8.3，1.9Hz，1H)7.01(d，J＝7.7Hz，1H)7.12(d，J＝1.8Hz，1H)7.22(d，J＝10.2Hz，1H)7.35(d，J＝8.4Hz，1H)8.02(d，J＝7.7Hz，1H)8.37(s，1H)11.97(br s，1H)

LC/MS (method LC-A): r_t1.19min，MH⁺531

Enantiomer 7A:

¹H NMR(400MHz，DMSO-d₆)δppm 2.30(d，J＝1.5Hz，3H)3.09(s，3H)3.72(s，3H)4.00(s，3H)6.22(d，J＝7.9Hz，1H)6.56-6.60(m，2H)6.91(t，J＝1.7Hz，1H)6.97(dd，J＝8.3，2.1Hz，1H)7.01(d，J＝7.7Hz，1H)7.12(d，J＝2.0Hz，1H)7.22(d，J＝10.1Hz，1H)7.34(d，J＝8.1Hz，1H)8.02(d，J＝7.7Hz，1H)8.37(s，1H)11.96(s，1H)

LC/MS (method LC-A): r_t1.15min，MH⁺531

[α]D20：-163.2°(c 0.435，DMF)

Chiral SFC (method SFC-E): r_t4.26min，MH⁺531, chiral purity 100%.

Enantiomer 7B:

¹H NMR(400MHz，DMSO-d₆)δppm 2.30(d，J＝1.5Hz，3H)3.09(s，3H)3.72(s，3H)4.00(s，3H)6.22(d，J＝7.7Hz，1H)6.57-6.61(m，2H)6.92(t，J＝1.8Hz，1H)6.97(dd，J＝8.1，2.0Hz，1H)7.01(d，J＝7.7Hz，1H)7.12(d，J＝2.0Hz，1H)7.22(d，J＝10.0Hz，1H)7.35(d，J＝8.4Hz，1H)8.02(d，J＝7.9Hz，1H)8.37(d，J＝2.4Hz，1H)11.97(s，1H)

LC/MS (method LC-A): r_t1.15min，MH⁺531

[α]_D ²⁰：+166.6°(c 0.5，DMF)

Chiral SFC (method SFC-E): r_t3.78min，MH⁺531, chiral purity 100%.

Example 8: synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (5- (trifluoromethyl) -1H-indol-3-yl) ethanone (compound 8) into enantiomers 8A and 8B.

Synthesis of intermediate 8 a:

at 0 ℃ under N₂Sodium hydride (2.48g, 64.8mmol) was added in portions to 5- (trifluoromethyl) -1H-indole [ CAS 100846-24-0 ] under flow](10g, 54.0mmol) in DMF (150mL) and the reaction mixture was stirred at 0 ℃ for 30 min. A solution of tosyl chloride (11.3g, 59.4mmol) in DMF (50mL) was added dropwise and the resulting mixture was stirred at room temperature for 3 h. At 0The mixture was quenched by the addition of water at deg.C. The precipitate was filtered off and dried under vacuum at 70 ℃ overnight to give 1-tosyl-5- (trifluoromethyl) -1H-indole 8a (18.4 g).

Synthesis of intermediate 8 b:

titanium (IV) chloride (2.4mL, 21.9mmol) was added dropwise to a solution of 1-tosyl-5- (trifluoromethyl) -1H-indole 8a (3.7g, 10.95mmol) and 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (4.8g, 21.9mmol, see example 1) in 1, 2-dichloroethane (120mL) at room temperature. The reaction was stirred at room temperature for 2 h. Ice water was added. The reaction mixture was extracted with EtOAc. The organic layer was purified over MgSO₄Dry, filter and concentrate the solvent under reduced pressure. By column chromatography on silica gel (15-40 μm, 80g, mobile phase: CH)₂Cl₂MeOH 99.5/0.5) to purify the residue. Fractions containing compound 8b were combined and the solvent was evaporated under reduced pressure. The compound is substituted by CH₃CN/diisopropyl ether absorption. The precipitate was filtered off and dried to give 2- (4-chloro-2-methoxyphenyl) -1- (1-tosyl-5- (trifluoromethyl) -1H-indol-3-yl) ethanone 8b (2.8 g).

Synthesis of intermediate 8 c:

lithium hydroxide (0.64g, 15.3mmol) was added to a solution of 2- (4-chloro-2-methoxyphenyl) -1- (1-tosyl-5- (trifluoromethyl) -1H-indol-3-yl) ethanone 8b (3.2g, 6.13mmol) in THF (18mL) and water (6 mL). The mixture was stirred at 30 ℃ for 1 h. Water and EtOAc were added. The organic layer was separated over MgSO₄Dry, filter and evaporate the solvent under reduced pressure. The solid was taken up in diisopropyl ether. The precipitate was filtered off and dried to give 2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethyl) -1H-indol-3-yl) ethanone 8c (2.1 g).

Synthesis of intermediate 8 d:

phenyltrimethylammoniumbromide [ CAS 4207-56-1] at 0 deg.C]A solution of (2.1g, 5.7mmol) in THF (60mL) was added dropwise to a mixture of 2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethyl) -1H-indol-3-yl) ethanone 8c (2.15g, 5.7mmol) in THF (60 mL). The mixture was stirred at 0 ℃ for 1h and at room temperature for 4 h. Will be provided withThe precipitate was filtered off and washed with EtOAc. The combined filtrates were concentrated under reduced pressure. The residue was dissolved in EtOAc. The organic layer was washed with water and MgSO₄Dry, filter and evaporate the solvent under reduced pressure. The residue was taken up in diisopropyl ether. The precipitate was filtered off and dried to give 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethyl) -1H-indol-3-yl) -ethanone 8d (2.5 g).

Synthesis of compound 8 and chiral separation into enantiomers 8A and 8B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethyl) -1H-indol-3-yl) ethanone 8d (1g, 2.24mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](496mg, 2.46mmol) and diisopropylethylamine (0.38mL, 2.24mmol) in CH₃A mixture of CN (50mL) and THF (25mL) was stirred at 70 ℃ for 24 h. The solution was concentrated under reduced pressure. The residue was dissolved in EtOAc and the solution was washed with 1N HCl. The organic layer was separated over MgSO₄Dry, filter and evaporate the solvent under reduced pressure. The compound is prepared from diisopropyl ether/CH₃CN to give 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (5- (trifluoromethyl) -1H-indol-3-yl) ethanone (compound 8, 310mg) as a racemic mixture.

Via preparative chiral SFC (stationary phase:

AD-H5 μm 250 × 20mm, mobile phase: 70% CO₂，30％iPrOH+0.3％iPrNH₂) The enantiomer of compound 8 was separated to give 122mg of the first eluting enantiomer 8A and 128mg of the second eluting enantiomer 8B after crystallization from petroleum ether/diisopropyl ether.

Compound 8:

¹H NMR(500MHz，DMSO-d₆)δppm 3.10(s，3H)3.72(s，3H)3.99(s，3H)6.29(d，J＝7.9Hz，1H)6.56-6.62(m，2H)6.92(s，1H)6.98(dd，J＝8.4，2.0Hz，1H)7.09(d，J＝7.9Hz，1H)7.13(d，J＝1.9Hz，1H)7.36(d，J＝8.5Hz，1H)7.54(dd，J＝8.5，1.6Hz，1H)7.69(d，J＝8.5Hz，1H)8.48(s，1H)8.61(s，1H)12.45(br s，1H)

LC/MS (method LC-C): r_t3.19min，MH⁺567

Melting point: 168 deg.C

Enantiomer 8A:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.73(s，3H)3.99(s，3H)6.29(d，J＝7.6Hz，1H)6.60(br s，2H)6.92(s，1H)6.98(dd，J＝8.3，1.8Hz，1H)7.07(d，J＝8.1Hz，1H)7.13(d，J＝1.5Hz，1H)7.36(d，J＝8.1Hz，1H)7.54(d，J＝8.1Hz，1H)7.69(d，J＝8.6Hz，1H)8.49(s，1H)8.60(s，1H)12.41(br s，1H)

LC/MS (method LC-C): r_t3.25min，MH⁺567

[α]_D ²⁰：-119.2°(c 0.2727，DMF)

Chiral SFC (method SFC-F): r_t2.64min，MH⁺567, chiral purity 100%.

Enantiomer 8B:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.73(s，3H)3.99(s，3H)6.29(d，J＝8.1Hz，1H)6.60(s，2H)6.92(s，1H)6.98(dd，J＝8.6，2.0Hz，1H)7.07(d，J＝8.1Hz，1H)7.13(d，J＝2.0Hz，1H)7.36(d，J＝8.6Hz，1H)7.54(dd，J＝8.6，1.5Hz，1H)7.69(d，J＝8.6Hz，1H)8.49(s，1H)8.60(s，1H)12.40(brs，1H)

LC/MS (method LC-C): r_t3.25min，MH⁺567

[α]_D ²⁰：+125.1°(c 0.2455，DMF)

Chiral SFC (method SFC-F): r_t3.44min，MH⁺567, chiral purity 100%.

Example 9: synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (5- (trifluoromethoxy) -1H-indol-3-yl) ethanone (compound 9) into enantiomers 9A and 9B.

Synthesis of intermediate 9 a:

reacting 5- (trifluoromethoxy) -1H-indole [ CAS 262593-63-5 ]](3g, 14.9mmol) in CH₂Cl₂(150mL) of solution in N₂Cooling to 0 ℃ under atmosphere. A solution of diethylaluminum chloride 1M in hexane (22.4mL, 22.4mmol) was added dropwise and the resulting mixture was kept at 0 ℃ for 15 min. 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (4.57g, 20.9mmol) was added dropwise to CH₂Cl₂(100 mL). Stirring was continued at 0 ℃ for 1h and subsequently the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was poured into a stirred ice/rochelle salt solution. After the ice has melted, the mixture is passed through

Filter and wash the filter cake several times with THF. The filtrates were combined. The layers were separated and the organic layer was washed with brine, MgSO₄Dried, filtered and evaporated under reduced pressure. The residue is treated with CH₂Cl₂(50mL) was ground. The resulting precipitate was filtered off and dried under vacuum at 50 ℃ to afford 2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 9a (4.39 g).

Synthesis of intermediate 9 b:

a stirred solution of 2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 9a (4.39g, 11.4mmol) in THF (200mL) was cooled to 0 ℃. A solution of phenyltrimethylammonium tribromide [ CAS 4207-56-1] (4.73g, 12.6mmol) in THF (100mL) was added dropwise. The resulting suspension was stirred at room temperature for 2 h. The solid was removed by filtration and washed with THF. The combined filtrates were evaporated under reduced pressure. The residue was mixed with EtOAc (30 mL). The solid was isolated by filtration, washed with a small amount of EtOAc and dried under vacuum at 50 ℃ to afford 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 9b (5.0g) as a white solid, which was used in the next step without further purification.

Synthesis of compound 9 and chiral separation of enantiomers 9A and 9B:

2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 9b (2.5g, 5.40mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ] -](1.49g, 7.38mmol) and diisopropylethylamine (931. mu.L, 5.40mmol) in CH₃The mixture in CN (100mL) was stirred at 90 ℃ overnight. The reaction mixture was concentrated under reduced pressure. Dissolving the residue in CH₂Cl₂(100mL), washed with 1N HCl (100mL) and water (100mL), over MgSO₄Dried, filtered and evaporated under reduced pressure. The residue is purified by column chromatography (stationary phase: Grace)

Silica 120g, mobile phase: EtOAc: EtOH (3: 1)/heptane gradient 0/100 to 50/50). The desired fractions were combined and evaporated under reduced pressure. The residue was precipitated from EtOAc (10mL) while stirring. The solid was isolated by filtration and washed with a small amount of EtOAc to afford 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (5- (trifluoromethoxy) -1H-indol-3-yl) ethanone as a racemic mixture (compound 9, 477 mg). The filtrate was evaporated under reduced pressure and the residue was taken up in EtOAc (5 mL). After stirring overnight, the solid was isolated by filtration and washed with EtOAc to provide a second crop of compound 9(216 mg).

Chiral separation of the enantiomer of compound 9(663mg) was carried out via normal phase chiral separation (stationary phase: AS 20 μm, mobile phase: 100% methanol). The product fractions were combined and evaporated to provide enantiomer 9A as the first eluted product and enantiomer 9B as the second eluted product. Enantiomer 9A in H at 40 deg.C₂O (2mL) and MeOH (3mL) with stirring. The solid is filtered off and washed with H₂O/MeOH 1/1 was washed (3 ×) and dried under vacuum at 45 ℃ to afford enantiomer 9A (151 mg). Enantiomer 9B was purified by flash chromatography on silica gel (stationary phase: Grace)

Silica 12g, mobile phase: heptane/EtOAc/EtOH 100/0/0 to 40/45/15). The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with EtOAc. The residue was stirred in MeOH (5mL) and washed by slow addition of H₂O (4mL) precipitated. The solid is filtered off and washed with H₂O/MeOH 1/1 was washed (3 ×) and dried under vacuum at 50 ℃ to afford enantiomer 9B (132 mg).

Compound 9:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.73(s，3H)3.99(s，3H)6.26(d，J＝7.9Hz，1H)6.57-6.62(m，2H)6.91(t，J＝1.9Hz，1H)6.98(dd，J＝8.4，2.0Hz，1H)7.07(d，J＝7.9Hz，1H)7.13(d，J＝2.0Hz，1H)7.22(dd，J＝8.6，2.2Hz，1H)7.36(d，J＝8.4Hz，1H)7.59(d，J＝8.8Hz，1H)8.06(d，J＝0.9Hz，1H)8.55(s，1H)12.28(br s，1H)

LC/MS (method LC-A): r_t1.31min，MH⁺583

Enantiomer 9A:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.73(s，3H)3.99(s，3H)6.26(d，J＝7.9Hz，1H)6.55-6.62(m，2H)6.91(t，J＝1.5Hz，1H)6.98(dd，J＝8.4，2.0Hz，1H)7.07(d，J＝7.9Hz，1H)7.13(d，J＝2.0Hz，1H)7.21(dd，J＝8.8，1.8Hz，1H)7.36(d，J＝8.4Hz，1H)7.59(d，J＝8.8Hz，1H)8.07(d，J＝0.9Hz，1H)8.55(s，1H)12.29(br s，1H)

LC/MS (method LC-A): r_t1.20min，MH⁺583

[α]_D ²⁰：+130.3°(c 0.555，DMF)

Chiral SFC (method SFC-E): r_t3.10min，MH⁺583, chiral purity 100%.

Enantiomer 9B:

¹H NMR(400MHz，DMSO-d₆)δppm 3.09(s，3H)3.73(s，3H)3.99(s，3H)6.26(d，J＝7.9Hz，1H)6.56-6.62(m，2H)6.92(t，J＝2.0Hz，1H)6.98(dd，J＝8.1，2.0Hz，1H)7.07(d，J＝7.9Hz，1H)7.13(d，J＝2.0Hz，1H)7.22(dd，J＝8.8，1.8Hz，1H)7.36(d，J＝8.4Hz，1H)7.59(d，J＝8.8Hz，1H)8.07(d，J＝0.9Hz，1H)8.55(s，1H)12.30(br s，1H)

LC/MS (method LC-A): r_t1.20min，MH⁺583

[α]_D ²⁰：-133.2°(c0.5，DMF)

Chiral SFC (method SFC-E): r_t3.50min，MH⁺583, chiral purity 100%.

Example 10: synthesis and chiral separation of 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (6-methoxy-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone (compound 10) into enantiomers 10A and 10B.

Synthesis of intermediate 10 a:

to 3-methoxy-4- (trifluoromethoxy) benzaldehyde [ CAS 853771-90-1 ]](50g, 230mmol) and ethyl azidoacetate (89g, 690mmol) in EtOH (400mL) in a cooled (-15 ℃ C.) solution over a period of 2h, a solution of NaOEt (0.69mol, prepared from 15.9g of Na and 700mL of EtOH) was added dropwise. The reaction mixture was stirred at room temperature overnight. After cooling on an ice bath, saturated NH was used₄The reaction was quenched with Cl solution (1.2L) and stirred for 10 min. The precipitate was filtered off, washed with water, and dried to give (Z) -ethyl 2-azido-3- (3-methoxy-4- (trifluoromethoxy) phenyl) acrylate 10a (32g) as a pale yellow solid.

Synthesis of intermediate 10 b:

under reflux, a solution of (Z) -ethyl 2-azido-3- (3-methoxy-4- (trifluoromethoxy) phenyl) acrylate 10a (3g, 10mmol) in xylene (40mL) was heated overnight. After cooling to room temperature, the solvent was evaporated to dryness. The residue was triturated with hexane (50mL), and the precipitate was filtered off to give methyl 6-methoxy-5- (trifluoromethoxy) -1H-indole-2-carboxylate 10b as a yellow solid (yield: 1.4-1.6 g).

Synthesis of intermediate 10 c:

to methyl 6-methoxy-5- (trifluoromethoxy) -1H-indole-2-carboxylate 10b (25g, 87mmol) in MeOH/H₂To the mixture in O (2/1, 300mL) NaOH (7g, 175mmol) was added and the mixture was heated under reflux until a clear solution was obtained. After cooling to room temperature, most of the methanol was removed under reduced pressure and the remaining aqueous solution was acidified with concentrated HCl to pH 3-4. The product was extracted with EtOAc (2 × 250 mL). The combined organic layers were washed with brine, dried, and evaporated under reduced pressure to give 6-methoxy-5- (trifluoromethoxy) -1H-indole-2-carboxylic acid 10c (22.7g) as a grey solid.

Synthesis of intermediate 10 d:

a suspension of 6-methoxy-5- (trifluoromethoxy) -1H-indole-2-carboxylic acid 10c (7.5g, 27mmol) and Cu (1.22g, 0.7 eq) in quinoline (150mL) was heated to 220 ℃ -230 ℃ under an inert atmosphere for 12H. After cooling to room temperature, the mixture was diluted with methyl tert-butyl ether (MTBE, 400mL) and saturated NaHSO₄Aqueous (2 × 500mL) wash. The organic layer was purified over MgSO₄Dry, filter through a short pad of silica gel, and evaporate under reduced pressure. The residue was purified by column chromatography to give 6-methoxy-5- (trifluoromethoxy) -1H-indole 10d (3.75g) as a yellow solid.

Synthesis of intermediate 10 e:

6-methoxy-5- (trifluoromethoxy) -1H-indole 10d (1.61g, 6.96mmol) in CH₂Cl₂(150mL) of solution in N₂Cooling to 0 ℃ under atmosphere. A solution of diethylaluminum chloride 1M in hexane (10.4mL, 10.4mmol) was added dropwise and the resulting mixture was kept at 0 ℃ for 15 min. 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (2.28g, 10.4mmol) was added dropwise to CH₂Cl₂(75 mL). Stirring was continued for 1h at 0 ℃ and for 1h at room temperature. The reaction mixture was cooled to 0 ℃ and a solution of sodium potassium tartrate tetrahydrate (rochelle salt, 3.93g, 13.9mmol) in water (6mL) was added dropwise. The reaction mixture was stirred at 0 ℃ for 30 min. THF (200mL) was added and the reaction mixture was stirred at room temperatureStirring for 20 min. Adding Na₂SO₄(25g) And the mixture was stirred overnight

Filter and wash the filter cake several times with THF (4x150 mL). The filtrates were combined and evaporated under reduced pressure. The solid residue was stirred in a mixture of diisopropyl ether (25mL) and EtOAc (2 mL). The solid was filtered off, washed with DIPE (3 ×) and dried under vacuum at 50 ℃ to afford 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 10e (3.6 g).

Synthesis of intermediate 10 f:

in N₂A stirred solution of 2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 10e (3.6g, 6.53mmol) in THF (130mL) was cooled to 0 ℃ under an atmosphere. Phenyl trimethyl ammonium tribromide [ CAS 4207-56-1] was added](2.58g, 6.85mmol) and the reaction mixture was stirred at 0 ℃ for 45min and at room temperature for 1.5 h. The solid was removed by filtration and washed with THF (2 ×). The combined filtrates were evaporated under reduced pressure to give 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 10f (4.16g), which was used in the next step without further purification.

Synthesis of compound 10 and chiral separation of enantiomers 10A and 10B:

in N₂Under an atmosphere of 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (6-methoxy-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 10f (4.16g, 6.50mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](2.62g, 13.0mmol) and diisopropylethylamine (2.24mL, 13.0mmol) in CH₃The mixture in CN was stirred at room temperature for 2 days. Water (250mL) was added and Et used₂The product was O (2X) extracted. The combined organic layers were dried over MgSO₄Dried, filtered and evaporated under reduced pressure. The residue is purified by column chromatography (stationary phase: Grace)

Silica 100g, mobile phase:heptane/EtOAc/EtOH gradient 100/0/0 to 40/45/15). The desired fractions were combined and evaporated under reduced pressure. The residue was purified by preparative HPLC (stationary phase: RP)

Preparation C18OBD-10 μm, 50X150 mm; mobile phase: 0.25% NH in Water₄HCO₃Solution of CH₃CN) for further purification. The desired fractions were combined and evaporated under reduced pressure. The residue comprising racemic 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (6-methoxy-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone (compound 10, 380mg) was subjected to purification by preparative SFC (stationary phase:

diacel AS 20x250mm, mobile phase: CO2₂，EtOH+0.4％iPrNH₂) Chiral separation was performed. The product fractions were combined, evaporated under reduced pressure, and co-evaporated with MeOH to afford enantiomer 10A as the first eluted product and enantiomer 10B as the second eluted product. Both enantiomers were precipitated from a solvent mixture of MeOH and water, filtered off and dried under vacuum at 50 ℃ to provide enantiomer 10A (135mg) and enantiomer 10B (144 mg).

Enantiomer 10A:

¹H NMR(360MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.87(s，3H)3.99(s，3H)6.22(d，J＝7.7Hz，1H)6.55-6.59(m，2H)6.88-6.91(m，1H)6.98(dd，J＝8.1，1.8Hz，1H)7.08(d，J＝7.7Hz，1H)7.13(d，J＝2.2Hz，1H)7.21(s，1H)7.34(d，J＝8.1Hz，1H)8.02(d，J＝1.5Hz，1H)8.41(s，1H)12.05(br s，1H)

LC/MS (method LC-A): r_t1.20min，MH⁺613

[α]_D ²⁰：+81.4°(c0.29，DMF)

Chiral SFC (method SFC-E): r_t3.34min，MH⁺613, chiral purity 100%.

Enantiomer 10B:

¹H NMR(360MHz，DMSO-d₆)δppm 3.09(s，3H)3.72(s，3H)3.87(s，3H)3.99(s，3H)6.22(d，J＝7.7Hz，1H)6.55-6.60(m，2H)6.90(t，J＝1.6Hz，1H)6.98(dd，J＝8.2，2.0Hz，1H)7.08(d，J＝7.8Hz，1H)7.13(d，J＝2.2Hz，1H)7.21(s，1H)7.34(d，J＝8.4Hz，1H)8.01(d，J＝1.1Hz，1H)8.41(s，1H)12.08(br s，1H)

LC/MS (method LC-A): r_t1.20min，MH⁺613

[α]_D ²⁰：-99.6°(c 0.261，DMF)

Chiral SFC (method SFC-E): r_t3.69min，MH⁺613, chiral purity 100%.

Example 11: synthesis of 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (7-methyl-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone (compound 11) and chiral separation into enantiomers 11A and 11B.

Synthesis of intermediate 11 a:

in N₂Under an atmosphere with CH₂Cl₂(20mL) diluted in CH₂Cl₂A mixture of boron (III) chloride 1M and aluminum (III) chloride (3.40g, 25.5mmol) (25.5mL, 25.5mmol) and cooled on an ice bath. Dropwise addition of 2-methyl-4- (trifluoromethoxy) aniline [ CAS 86256-59-9 ]](4.88g, 25.5mmol) and chloroacetonitrile (3.24mL, 51.0mmol) in CH₂Cl₂(7.5 mL). After addition, the ice bath was removed and the mixture was heated at reflux for 8 h. The mixture was cooled again to 0 ℃ using an ice bath. 2N HCl (75mL) was added dropwise, causing severe precipitation. The resulting suspension was heated at reflux for 90min and cooled to room temperature. The solids were removed by filtration. By CH₂Cl₂(4X) washing the filter cake. The filtrates were combined and the phases were separated. Separating the organic layer with NaHCO₃Washing with an aqueous solution over MgSO₄Dried, filtered and evaporated under reduced pressure. The solid phase was purified by flash chromatography (stationary phase:

SNAP Ultra silica 100g, mobile phase: heptane/CH₂Cl₂Gradient 100/0 to 0/100) to purify the residue. The desired fractions were combined and concentrated to a residual volume of 30 mL. The precipitate is filtered off with heptane and CH₂Cl₂Washed and dried under vacuum at 50 ℃ to afford 1- (2-amino-3-methyl-5- (trifluoromethoxy) phenyl) -2-chloroacetone 11a (1.37 g). The filtrate was concentrated under reduced pressure. The solid residue was stirred in a mixture of heptane (20mL) and diisopropyl ether (3mL), filtered off, washed with heptane (3 ×) and dried under vacuum at 50 ℃ to afford a second fraction of 11a (0.24 g).

Synthesis of intermediate 11 b:

sodium borohydride (326mg, 8.61mmol) was added to a stirred solution of 1- (2-amino-3-methyl-5- (trifluoromethoxy) phenyl) -2-chloroethone 11a (1.92g, 7.17mmol) in tert-butanol (50mL) and water (5 mL). The reaction mixture was stirred at room temperature for 30min and at 90 ℃ for 2.5 h. Water (50mL) was added and the product extracted with ether (2 ×). The combined organic layers were washed with brine, over MgSO₄Dried, filtered and evaporated under reduced pressure. The solid phase was purified by flash chromatography (stationary phase:

SNAP Ultra silica 25g, mobile phase: heptane/EtOAc gradient 100/0 to 20/80). The desired fractions were combined and concentrated under reduced pressure, co-evaporated with heptane and dried under vacuum at 50 ℃ to give 7-methyl-5- (trifluoromethoxy) -1H-indole 11b (1.2 g).

Synthesis of intermediate 11 c:

7-methyl-5- (trifluoromethoxy) -1H-indole 11b (1.5g, 6.97mmol) in CH₂Cl₂(100mL) mechanically stirred solution in N₂Cooling to 0 ℃ under atmosphere. A solution of diethylaluminum chloride 1M in hexane (10.5mL, 10.5mmol) was added dropwise and the resulting mixture was addedKeeping at 0 deg.C for 25 min. 2- (4-chloro-2-methoxyphenyl) acetyl chloride 1a (2.29g, 10.5mmol) was added dropwise to CH₂Cl₂(40mL) while maintaining the reaction temperature below 6 ℃. Stirring was continued for 1h at 0 ℃ and subsequently the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was cooled to 0 ℃ and Rochelle salt [ CAS 6100-16-9) was added dropwise in water (4mL)](3.94g, 13.9 mmol). After stirring for 1h, the reaction mixture was filtered

Filter and wash the filter cake with THF (5x100 mL). The combined filtrates were evaporated under reduced pressure. The residue was solidified by standing overnight. In CH₃CN (5mL) was stirred, filtered off and washed with CH₃CN (3 × 1.5ml) was washed and dried under vacuum at 50 ℃ to afford 2- (4-chloro-2-methoxyphenyl) -1- (7-methyl-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 11c (1.9 g).

Synthesis of intermediate 11 d:

in N₂A stirred solution of 2- (4-chloro-2-methoxyphenyl) -1- (7-methyl-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 11c (2.13g, 5.35mmol) in THF (80mL) was cooled to 0 ℃ under an atmosphere. Phenyl trimethyl ammonium tribromide [ CAS 4207-56-1] was added](2.11g, 5.62mmol) and the reaction mixture was stirred at 0 ℃ for 40min and at room temperature for 2 h. The solid was removed by filtration and washed with THF (2 ×). The combined filtrates were evaporated under reduced pressure to give 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (7-methyl-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 11d (3.45g), which was used in the next step without further purification.

Synthesis of compound 11 and chiral separation of enantiomers 11A and 11B:

in N₂Under an atmosphere of 2-bromo-2- (4-chloro-2-methoxyphenyl) -1- (7-methyl-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone 11d (3.45g, 6.87mmol), 3-methoxy-5- (methylsulfonyl) aniline [ CAS 62606-02-4 [ ]](2.76g, 13.7mmol) and diisopropylethylamine (2.37mL, 13.7mmol) in CH₃The mixture in CN (60mL) was stirred at room temperature for 2 days. Water (125mL) and Et₂The product was O (2X) extracted. The combined organic layers were washed with brine, over MgSO₄Dried, filtered and evaporated under reduced pressure. The residue was purified by preparative HPLC (stationary phase: RP)

Preparation type C18OBD-10 μm, 50X150 mm; mobile phase: 0.25% NH in Water₄HCO₃Solution of CH₃CN) was added. The product-containing fractions were combined and evaporated under reduced pressure to give racemic 2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (7-methyl-5- (trifluoromethoxy) -1H-indol-3-yl) ethanone (compound 11, 1.74 g). Via preparative SFC (stationary phase:

diacel AS 20x250mm, mobile phase: CO2₂，EtOH+0.4％iPrNH₂) Chiral separation of the enantiomer of compound 11(1.74g) was performed. The product fractions were combined and evaporated under reduced pressure to afford enantiomer 11A as the first eluted product and enantiomer 11B as the second eluted product. Both enantiomers were precipitated from a solvent mixture of MeOH and water, filtered off and dried under vacuum at 50 ℃ to afford enantiomer 11A (777mg) and enantiomer 11B (712 mg).

Enantiomer 11A:

¹H NMR(600MHz，DMSO-d₆)δppm2.50(s，3H)3.09(s，3H)3.72(s，3H)4.00(s，3H)6.28(d，J＝7.8Hz，1H)6.56-6.63(m，2H)6.92(br s，1H)6.97(dd，J＝8.4，1.9Hz，1H)7.05(br s，1H)7.07(d，J＝7.9Hz，1H)7.13(d，J＝1.9Hz，1H)7.35(d，J＝8.4Hz，1H)7.90(br s，1H)8.53(s，1H)12.41(br s，1H)

LC/MS (method LC-A): r_t1.26min，MH⁺597

[α]_D ²⁰：+81.3°(c 0.3455，DMF)

Chiral SFC (method SFC-E): r_t2.96min，MH⁺597, chiral purity 100%.

Enantiomer 11B:

¹H NMR(600MHz，DMSO-d₆)δppm 2.51(s，3H)3.09(s，3H)3.72(s，3H)4.00(s，3H)6.28(d，J＝7.9Hz，1H)6.58-6.60(m，2H)6.92(t，J＝1.8Hz，1H)6.97(dd，J＝8.4，1.9Hz，1H)7.05(br s，1H)7.06(d，J＝7.9Hz，1H)7.13(d，J＝2.1Hz，1H)7.35(d，J＝8.2Hz，1H)7.89(br s，1H)8.53(s，1H)12.37(br s，1H)

LC/MS (method LC-A): r_t1.26min，MH⁺597

[α]_D ²⁰：-87.4°(c 0.342，DMF)

Chiral SFC (method SFC-E): r_t3.44min，MH⁺597, chiral purity 100%.

Antiviral Activity of Compounds of the invention

DENV-2 antiviral assay

The antiviral activity of all compounds of the invention was tested against DENV-216681 strain, which was labeled with enhanced green fluorescent protein (eGPF; Table 1). The medium consisted of minimal essential medium supplemented with 2% heat-inactivated fetal bovine serum, 0.04% gentamicin (50mg/mL) and 2mM L-glutamine. Vero cells obtained from ECACC were suspended in culture medium and 25 μ Ι _ were added to 384 well plates (2500 cells/well) which already contained the antiviral compound. Typically, these plates contain 5-fold serial dilutions of 9 dilution steps of test compounds at 200-fold of the final concentration in 100% DMSO (200 nL). In addition, each compound concentration was tested in quadruplicate (final concentration range: 25. mu.M-0.000064. mu.M or 2.5. mu.M-0.0000064. mu.M for most active compounds). Finally, each plate contains wells designated as virus control (containing cells and virus in the absence of compound), cell control (containing cells in the absence of virus and compound), and media control (containing media in the absence of cells, virus, and compound). To these wells designated as media controls, 25 μ L of media was added instead of Vero cells. Once cells were added to the plates, the plates were incubated at room temperature for 30 minutes toThe cells are allowed to distribute evenly within the pores. Next, the plates were placed in a completely wet incubator (37 ℃, 5% CO)₂) Until the next day. Then, DENV-2 strain 16681 labeled with eGFP was added at a multiplicity of infection (MOI) of 0.5. Thus, 15 μ Ι _ of viral suspension was added to all wells containing test compound and to wells designated as virus control. In parallel, 15 μ Ι _ of medium was added to the medium control and the cell control. Next, the plates were placed in a completely wet incubator (37 ℃, 5% CO)₂) And (3) incubating. On the day of readout, eGFP fluorescence was measured using an automated fluorescence microscope at 488nm (blue laser). Using an internal LIMS system, an inhibitory dose-response curve for each compound was calculated and the half-maximal Effective Concentration (EC) was determined₅₀). Thus, the percentage inhibition (I) was calculated for each tested concentration using the following formula: 100 ═ S (S)_T-S_CC)/(S_VC-S_CC)；S_T、S_CCAnd S_VCThe amount of eGFP signal in test compound wells, cell control wells, and virus control wells, respectively. EC (EC)₅₀Represents the concentration of compound at which viral replication is inhibited by 50%, as measured by a 50% reduction in eGFP fluorescence intensity compared to a viral control. Calculating EC using linear interpolation₅₀。

In parallel, the toxicity of these compounds was assessed on the same plate. Once a readout of eGFP signal was performed, 40 μ L of ATPlite (a cell viability stain) was added to all wells of the 384 well plates. ATP is present in all metabolically active cells and the concentration drops very rapidly when the cells undergo necrosis or apoptosis. The ATPLite assay system is based on the generation of light by the reaction of ATP with added luciferase and luciferin. The plates were incubated at room temperature for 10 minutes. Next, the plates were measured on a ViewLux. The half maximal Cytotoxic Concentration (CC) was also determined₅₀) Defined as the concentration required to reduce the luminescence signal by 50% compared to that of the cell control wells. Finally, the Selectivity Index (SI) of these compounds was determined, which index was calculated as follows: SI ═ CC₅₀/EC₅₀。

₅₀ ₅₀Table 1: EC, CC and SI of the Compounds of the invention in a DENV-2 antiviral assay

N-the number of independent experiments performed on these compounds.

Tetravalent reverse transcriptase quantitative-PCR (RT-qPCR) assay: scheme A.

Compounds of the invention were tested for antiviral activity against DENV-1 strain TC974#666 (NCPV; Table 6), DENV-2 strain 16681 (Table 7), DENV-3 strain H87 (NCPV; Table 8) and DENV-4 strain H241 (NCPV; Table 9A) and SG/06K2270DK1/2005 (Eden; Table 9B) in RT-qPCR assays. Thus, Vero cells were infected with either DENV-1 or DENV-2 or DENV-3 or DENV-4 in the presence or absence of the test compound. On day 3 post-infection, cells were lysed and cell lysates used to prepare cdnas for both viral targets (3' UTR of DENV; table 2) and cellular reference genes (β -actin, table 2). Subsequently, double real-time PCR was performed on a Lightcycler480 instrument. The Cp values generated are inversely proportional to the amount of RNA expression of these targets. Inhibition of DENV replication by the test compound results in a shift in Cp of the 3' UTR gene. On the other hand, if the test compound is toxic to these cells, a similar effect on β -actin expression will be observed. Comparative Delta Cp method for calculating EC₅₀The method is based on the relative gene expression of the target gene (3' UTR) normalized with the cytohousekeeping gene (β -actin).

Table 2: primers and probes for real-time quantitative RT-PCR.

^aThe reporter dye (FAM, HEX) and quencher (ZEN and IABkFQ) elements are indicated in bold and italics.

^bThese guidesThe nucleotide sequences of the substances and probes were selected from conserved regions in the 3' UTR region of the dengue virus genome, which is based on an alignment of 300 nucleotide sequences of the four dengue serotypes deposited at Genbank (Gong et al, 2013, Methods in molecular biology (Methods Mol Biol), Chapter 16).

The medium consisted of minimal essential medium supplemented with 2% heat-inactivated fetal bovine serum, 0.04% gentamicin (50mg/mL) and 2mM L-glutamine. Vero cells obtained from ECACC were suspended in culture medium and 75 μ Ι/well were added in 96-well plates (10000 cells/well) which already contained the antiviral compound. Typically, these plates contain 5-fold serial dilutions of 9 dilution steps of the test compound at 200-fold the final concentration in 100% DMSO (500 nL; final concentration range: 25. mu.M-0.000064. mu.M or 2.5. mu.M-0.0000064. mu.M for most active compounds). In addition, each plate contains wells designated as a viral control (containing cells and virus in the absence of compound) and a cellular control (containing cells in the absence of virus and compound). Once the cells were added to the plates, the plates were placed in a fully wetted incubator (37 ℃, 5% CO)₂) Until the next day. Dengue virus serotypes 1, 2, 3 and 4 were diluted to obtain Cp of about 22-24 in the assay. Thus, 25 μ Ι _ of viral suspension was added to all wells containing test compound and to wells designated as virus control. In parallel, 25 μ Ι _ of medium was added to the cell control. Next, the plates were placed in a completely wet incubator (37 ℃, 5% CO)₂) And (3) incubating. After 3 days, the supernatant was removed from the wells and the wells were washed twice with ice-cold PBS (about 100 μ L). The cell pellets in these 96-well plates were stored at-80 ℃ for at least 1 day. Next, the Cells-to-CT was used according to the manufacturer's instructions (Life Technologies)^TMAnd (4) extracting RNA by using the lysis kit. These cell lysates can be stored at-80 ℃ or used immediately in the reverse transcription step.

In preparation for the reverse transcription step, mix a (table 3A) was prepared and 7.57 μ Ι _ wells were dispensed in 96-well plates. After the addition of 5 μ L of cell lysate, a five minute denaturation step at 75 ℃ was performed (table 3B). Thereafter, 7.43 μ L of mixture B (table 3C) was added and the reverse transcription step (table 3D) was initiated to generate cDNA.

Finally, RT-qPCR mixtures were prepared, mixture C (table 4A), and the mixtures (22.02 μ L/well) were dispensed into 96 well LightCycler qPCR plates, 3 μ L of cDNA was added to these plates, and qPCR was performed on LightCycler480 according to the conditions in table 4B.

Dose response curves for each compound were calculated using LightCycler software and an internal LIMS system, and half maximal Effective Concentrations (EC) were determined₅₀) And half maximal Cytotoxic Concentration (CC)₅₀)。

Table 3: cDNA synthesis was performed using mixture A, denaturation, mixture B and reverse transcription.

A mixture A

B, denaturation step:

step (ii) of	Temperature of	Time
			Denaturation of the material	75℃	5′
Holding	4℃	Holding

C mixture B

Scheme D cDNA Synthesis

Step (ii) of	Temperature of	Time
			Reverse transcription	42℃	30′
Denaturation of the material	99℃	5′
			Holding	4℃	Holding

Table 4: qPCR mixtures and protocols.

A mixture C

Protocol B qPCR3

Tetravalent quantitative reverse transcriptase-PCR (RT-qPCR) assay: scheme B.

The compounds of the invention were tested for antiviral activity against the DENV-1 strain Djibroti strain (D1/H/IMTSSA/98/606; Table 6), the DENV-2 strain NGC (Table 7), the DENV-3 strain H87 (Table 8) and the DENV-4 strain SG/06K2270DK1/2005 (Table 9B) in an RT-qPCR assay. Vero-B or Vero-M cells (5X 10)⁴) Seeded in 96-well plates. One day later, the cell culture medium was replaced with 100. mu.L of assay medium containing 2X, 3X or 5X serial dilutions of the compound (concentration ranges: 50. mu.g/mL-0.00038. mu.g/mL, 50. mu.g/mL-0.0076. mu.g/mL and 50. mu.g/mL-0.00013. mu.g/mL, respectively) and 100. mu.L of dengue virus inoculum (DENV). After a 2 hour incubation period, the cell monolayer was washed 3 times with assay medium to remove residues, and the unadsorbed virus and culture were further incubated for either 4 days (DENV-2 NGC) or 7 days (DENV-1 Djibrouti strain D1/H/IMTSSA/98/606, DENV-3 strain H87 prototype, DENV-4 strain H241, and DENV-4 strain EDEN) in the presence of inhibitors. Supernatants were harvested and viral DNA load was determined by real-time quantitative RT-PCR. 50% Effective Concentration (EC) was determined using logarithmic interpolation₅₀) (which is defined as the concentration of compound required to inhibit viral RNA replication by 50%).

Using NucleoSpin 96 Virus kit (Filter Service, Dilun)

Germany) RNA was isolated from 100 μ L (or in some cases 150 μ L) supernatant as described by the manufacturer. TaqMan primers (DENV-For, DENV-Rev; Table 5) and TaqMan probes (DENV-probes)Table 5) sequences were expressed using primer expression software (version 2.0; applied Biosystems, lenik (Lennik), belgium, was selected from the non-structural gene 3(NS3) or NS5 of the corresponding flavivirus. TaqMan probes were fluorescently labeled with 6-carboxyfluorescein (FAM) as a reporter dye at the 5 'end and with Minor Groove Binder (MGB) as a quencher at the 3' end (Table 5). One-step quantitative RT-PCR was performed in a total volume of 25. mu.L containing 13.9375. mu. L H₂O, 6.25. mu.L of master mix (Eurogentec, Seraing, Belgium), 0.375. mu.L of forward primer, 0.375. mu.L of reverse primer, 1. mu.L of probe, 0.0625. mu.L of reverse transcriptase (Eurogentec) and 3. mu.L of sample. RT-PCR was performed using an ABI 7500 rapid real-time PCR system (applied biosystems, branhburg, New Jersey, usa) using the following conditions: 30min at 48 ℃ and 10min at 95 ℃ followed by 40 cycles of 15s at 95 ℃ and 1min at 60 ℃. Data were analyzed using ABI PRISM 7500 SDS software (version 1.3.1; applied biosystems). For absolute quantification, a standard curve was generated using 10-fold dilutions of the template formulation with known concentrations.

Table 5: primers and probes for real-time quantitative RT-PCR.

^aThe reporter dye (FAM) and quencher (MGB/TAMRA) elements are indicated in bold and italics.

^bThe nucleotide sequences and positions of primers and probes within the genome were deduced from DENV 2 NGC (GenBank accession M29095; Nethereto (Irie) et al, 1989), dengue virus serotype 1 Djibouti strain D1/H/IMTSSA/98/606(Genbank accession AF298808), dengue virus serotype 3 strain H87 prototype (c93130), dengue virus serotype 4 strain H241 (no available sequence), dengue virus serotype 4 strainNucleotide sequence of EDEN (unavailable sequence).

Cytotoxicity assays

The potential cytotoxic effects of these compounds were evaluated in uninfected resting Vero-B or Vero-M cells. Cells were treated at 5X 10. mu.g/mL in the presence of two-, three-or five-fold serial dilutions of the compound (ranging from 50. mu.g/mL-0.0038. mu.g/mL, 50. mu.g/mL-0.0076. mu.g/mL and 50. mu.g/mL-0.00013. mu.g/mL, respectively)⁴Individual cells/well were seeded in 96-well plates and incubated for 4 to 7 days. The medium was discarded and 100. mu.L of 3- (4, 5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium/phenazine methosulfate (MTS/PMS; Promega, Leiden, Netherlands) in PBS was added to each well. After incubation at 37 ℃ for a period of 2 hours, the optical density was determined at 498 nm. The cytotoxic activity was calculated using the following formula: cell viability%_{Compound (I)}/ODCC) wherein OD_{Compound (I)}And OD_CCCorresponding to the optical density at 498nm of the uninfected cell culture treated with the compound and the optical density at 498nm of the uninfected, untreated cell culture, respectively. The 50% cytotoxic concentration (i.e., the concentration that reduces total cell number by 50%; CC) was calculated using linear interpolation₅₀)。

₅₀ ₅₀Table 9: compounds against EC, CC and SI of serotype 4 in RT-qPCR assays

A

N-the number of independent experiments performed on these compounds.

B

N-the number of independent experiments performed on these compounds.

Sequence listing

<110> Yanseng pharmaceutical Co., Ltd

Luwen university of heaven

<120> monosubstituted or disubstituted indole derivatives as inhibitors of dengue virus replication

<130> TIP 328 PCT

<150> EP15166900.9

<151> 2015-05-08

<150> EP16163342.5

<151> 2016-03-31

<160> 14

<170> BiSSAP 1.2

<210> 1

<211> 20

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..20

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 1

tcggagccgg agtttacaaa 20

<210> 2

<211> 20

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..20

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 2

tcttaacgtc cgcccatgat 20

<210> 3

<211> 19

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..19

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 3

attccacaca atgtggcat 19

<210> 4

<211> 23

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..23

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 4

ggatagacca gagatcctgc tgt 23

<210> 5

<211> 20

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..20

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 5

cattccattt tctggcgttc 20

<210> 6

<211> 20

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..20

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 6

caatccatct tgcggcgctc 20

<210> 7

<211> 20

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..20

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 7

cagcatcatt ccaggcacag 20

<210> 8

<211> 20

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..20

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 8

caacatcaat ccaggcacag 20

<210> 9

<211> 19

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..19

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 9

cggttagagg agacccctc 19

<210> 10

<211> 21

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..21

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 10

gagacagcag gatctctggt c 21

<210> 11

<211> 28

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..28

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 11

aaggactaga ggttagagga gacccccc 28

<210> 12

<211> 18

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..18

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 12

ggccaggtca tcaccatt 18

<210> 13

<211> 21

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..21

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 13

atgtccacgt cacacttcat g 21

<210> 14

<211> 21

<212> DNA

<213> dengue virus

<220>

<221> sources

<222> 1..21

<223 >/organism = "dengue virus"

Molecular type = "unassigned DNA"

<400> 14

ttccgctgcc ctgaggctct c 21

Claims

1. A compound of formula (I)

A stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof, the compound comprising a mono- or di-substituted indole group; the compound is selected from the group consisting of:

R1 is H, R2 is _F and _R3 is H or _CH3 _,

R ₁ is H, CH ₃ or F, R ₂ is OCH ₃ and R ₃ is H and

R ₁ is H, R ₂ is OCH ₃ and R ₃ is CH ₃ ,

R1 is _CH3 , _R2 is _F and _R3 is H,

R1 is _CF3 or _OCF3 , _R2 is H and _R3 _is H,

R ₁ is OCF ₃ , R ₂ is OCH ₃ and R ₃ is H and

R ₁ is OCF ₃ , R ₂ is H and R ₃ is CH ₃ .

2. The compound of claim 1, or a stereoisomeric form thereof, a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein the compound is selected from the group consisting of:

3. A pharmaceutical composition comprising a compound of formula (I) or a stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or 2 , together with one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A compound of formula (I) according to claim 1 or a stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof, or a pharmaceutical composition according to claim 3, Used as a medicine.

5. A compound of formula (I) according to claim 1 or a stereoisomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof, or a pharmaceutical composition according to claim 3, For use in the treatment of dengue fever.

6. A compound represented by the following structural formula (I)

R1 is H, R2 is _F and _R3 is H or _CH3 _,

R ₁ is H, CH ₃ or F, R ₂ is OCH ₃ and R ₃ is H and

R ₁ is H, R ₂ is OCH ₃ and R ₃ is CH ₃ ,

R1 is _CH3 , _R2 is _F and _R3 is H,

R1 is _CF3 or _OCF3 , _R2 is H and _R3 _is H,

R ₁ is OCF ₃ , R ₂ is OCH ₃ and R ₃ is H and

R ₁ is OCF ₃ , R ₂ is H and R ₃ is CH ₃

Use for inhibiting the replication of one or more dengue viruses in a biological sample or patient.

7. The use of the compound of claim 6, further comprising co-administering an additional therapeutic agent.

8. The use of claim 7, wherein the additional therapeutic agent is selected from an antiviral agent or a dengue vaccine or both.